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A B S T R A C T
Background
Plague is a severe disease associated with high mortality. Late diagnosis leads to advance stage of the disease with worse outcomes and
higher risk of spread of the disease. A rapid diagnostic test (RDT) could help in establishing a prompt diagnosis of plague. This would
improve patient care and help appropriate public health response.
Objectives
To determine the diagnostic accuracy of the RDT based on the antigen F1 (F1RDT) for detecting plague in people with suspected disease.
Search methods
We searched the CENTRAL, Embase, Science Citation Index, Google Scholar, the World Health Organization International Clinical Trials
Registry Platform and ClinicalTrials.gov up to 15 May 2019, and PubMed (MEDLINE) up to 27 August 2019, regardless of language,
publication status, or publication date. We handsearched the reference lists of relevant papers and contacted researchers working in the
field.
Selection criteria
We included cross-sectional studies that assessed the accuracy of the F1RDT for diagnosing plague, where participants were tested with
both the F1RDT and at least one reference standard. The reference standards were bacterial isolation by culture, polymerase chain reaction
(PCR), and paired serology (this is a four-fold diHerence in F1 antibody titres between two samples from acute and convalescent phases).
Data collection and analysis
Two review authors independently selected studies and extracted data. We appraised the methodological quality of each selected studies
and applicability by using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. When meta-analysis was appropriate,
we used the bivariate model to obtain pooled estimates of sensitivity and specificity. We stratified all analyses by the reference standard
used and presented disaggregated data for forms of plague. We assessed the certainty of the evidence using GRADE.
Main results
We included eight manuscripts reporting seven studies. Studies were conducted in three countries in Africa among adults and children
with any form of plague. All studies except one assessed the F1RDT produced at the Institut Pasteur of Madagascar (F1RDT-IPM) and one
study assessed a F1RDT produced by New Horizons (F1RDT-NH), utilized by the US Centers for Disease Control and Prevention. We could
not pool the findings from the F1RDT-NH in meta-analyses due to a lack of raw data and a threshold of the test for positivity diHerent from
the F1RDT-IPM.
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Risk of bias was high for participant selection (retrospective studies, recruitment of participants not consecutive or random, unclear
exclusion criteria), low or unclear for index test (blinding of F1RDT interpretation unknown), low for reference standards, and high or
unclear for flow and timing (time of sample transportation was longer than seven days, which can lead to decreased viability of the
pathogen and overgrowth of contaminating bacteria, with subsequent false-negative results and misclassification of the target condition).
F1RDT for diagnosing all forms of plague
F1RDT-IPM pooled sensitivity against culture was 100% (95% confidence interval (CI) 82 to 100; 4 studies, 1692 participants; very low
certainty evidence) and pooled specificity was 70.3% (95% CI 65 to 75; 4 studies, 2004 participants; very low-certainty evidence).
The performance of F1RDT-IPM against PCR was calculated from a single study in participants with bubonic plague (see below).
There were limited data on the performance of F1RDT against paired serology.
F1RDT for diagnosing pneumonic plague
Performed in sputum, F1RDT-IPM pooled sensitivity against culture was 100% (95% CI 0 to 100; 2 studies, 56 participants; very low-certainty
evidence) and pooled specificity was 71% (95% CI 59 to 80; 2 studies, 297 participants; very low-certainty evidence).
There were limited data on the performance of F1RDT against PCR or against paired serology for diagnosing pneumonic plague.
F1RDT for diagnosing bubonic plague
Performed in bubo aspirate, F1RDT-IPM pooled sensitivity against culture was 100% (95% CI not calculable; 2 studies, 1454 participants;
low-certainty evidence) and pooled specificity was 67% (95% CI 65 to 70; 2 studies, 1198 participants; very low-certainty evidence).
Performed in bubo aspirate, F1RDT-IPM pooled sensitivity against PCR for the caf1 gene was 95% (95% CI 89 to 99; 1 study, 88 participants;
very low-certainty evidence) and pooled specificity was 93% (95% CI 84 to 98; 1 study, 61 participants; very low-certainty evidence).
There were no data providing data on both F1RDT and paired serology for diagnosing bubonic plague.
Authors' conclusions
Against culture, the F1RDT appeared highly sensitive for diagnosing either pneumonic or bubonic plague, and can help detect plague in
remote areas to assure management and enable a public health response. False positive results mean culture or PCR confirmation may be
needed. F1RDT does not replace culture, which provides additional information on resistance to antibiotics and bacterial strains.
P L A I N   L A N G U A G E   S U M M A R Y
Rapid diagnostic tests for plague
Why is improving diagnosis of plague important?
Plague is a severe disease associated with high death rates. Pneumonic plague mainly aHects the lungs, while bubonic plague present with
painful swellings. Not recognizing plague early may result in delayed diagnosis and treatment associated with advanced illness and death,
and increased disease spread. A rapid diagnostic test (RDT) could help prompt diagnosis of plague, especially in low-resource settings. This
would improve patient care and help appropriate response to avoid the disease spread.
What is the aim of this review?
To assess the accuracy of the F1RDT for detecting plague in people with suspected plague.
What was studied in this review?
F1RDT is a test that detects the F1 antigen, which is part of the outer surface of Yersinia pestis, the bacteria causing plague. The test is
simple to perform and provides a result within 15 minutes. It can be performed in the pus contained in the buboes (swellings), or in the
sputum (mucous coughed up from the respiratory tract) of people with suspected pneumonic plague. We measured the results of F1RDT
against culture, molecular test, or serological tests.
What are the main results?
Seven studies (reported in eight manuscripts) provided findings of F1RDT used in people with suspected plague in three African countries.
For any form of plague and when compared to culture, F1RDT registered positive in 100% (sensitivity, which measures a test's ability to
correctly identify a positive result for the disease) of people who had plague and registered negative in 70% of people who actually did not
have plague (specificity, which measures a test's ability to correctly generate a negative result for people who do not have the condition
that is being tested for).
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For pneumonic plague, sensitivity was 100% and specificity 71% compared to culture.
For bubonic plague, sensitivity was 100% and specificity 67% compared to culture. Compared to a molecular test for bubonic plague,
sensitivity was 95% and specificity 93%.
How confident are we in the review's results?
Overall, the reliability of the evidence was very low. Results should be interpreted with caution. There were concerns about the quality
of the methodology of all included studies. Also, culture might not work well as a reference standard (comparator) when people received
antibiotics before sample collection for testing.
What do the results mean?
In a hypothetical population of 1000 people:
• with symptoms of pneumonic plague where 40 of them have the disease confirmed by culture, the utilization of F1RDT would result in:
318 people to be F1RDT-positive, of which 278 would not have pneumonic plague (called false positives); and 682 people to be F1RDT-
negative, of which none would have pneumonic plague (called false negatives).
• with symptoms of bubonic plague where 40 of them have the disease confirmed by culture, the utilization of F1RDT would result in: 357
people to be F1RDT-positive, of which 317 would not have bubonic plague (false positives); and 643 people to be F1RDT-negative, of which
none would have bubonic plague (false negatives).
• with symptoms of bubonic plague where 40 of them have the disease confirmed by molecular test, the utilization of F1RDT would result
in: 105 people to be F1RDT-positive, of which 67 would not have bubonic plague (false positives); and 895 people to be F1RDT-negative,
of which two would have bubonic plague (false negatives).
Who do the review's results apply to?
Adults and children with suspected bubonic or pneumonic plague.
What are the implications of this review?
F1RDT appears to be highly sensitive for pneumonic or bubonic plague. As a simple test that can be performed at a patient's bedside in
remote and low-resource areas, F1RDT can assist with plague diagnosis for early management, and appropriate preventive measures to
avoid spread of the disease.
The number of false positives (people with a positive F1RDT but who do not have plague) indicate that F1RDT may need to be combined
with other laboratory evaluations (culture or molecular test) to confirm the diagnosis of plague.
F1RDT does not replace culture, which provides additional information on resistance to antibiotics and bacterial strains.
How up-to-date is this review?
The review authors searched for studies up to 15 May 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   F1RDT against culture for all forms of plague
Review question: what is the diagnostic accuracy of F1RDT for the diagnosis of plague in adults and children?
Setting: populations where plague has been known to occur and populations where an outbreak is in progress
Patient or population: adults and children with suspicion of plague
Index test: F1RDT from Institut Pasteur of Madagascar
Reference standard: culture
Study design: retrospective reports
Pooled sensitivity: 1.00 (95% CI 0.82 to 1.00). Pooled specificity: 0.70 (95% CI 0.65 to 0.75)
Number of results per 1000 participants tested (95% CI)aTest result
Prevalence 0.1% Prevalence 4% Prevalence 20%
Number
of par-
ticipants
(studies)
Certainty of
the evidence
(GRADE)
True positives (participants correctly classified as having plague) 1 (1 to 1) 40 (33 to 40) 200 (164 to 200)
False negatives (participants incorrectly classified as not having
plague)
0 (0 to 0) 0 (0 to 7) 0 (0 to 36)
1692 (4) ⊕⊝⊝⊝
Very low b,c,d
True negatives (participants correctly classified as not having
plague)
699 (649 to 749) 672 (624 to 720) 560 (520 to 600)
False positives (participants incorrectly classified as having
plague)
300 (250 to 350) 288 (240 to 336) 240 (200 to 280)
2004 (4) ⊕⊝⊝⊝
Very low b,d,e
aThe table displays normalized frequencies within a hypothetical cohort of 1000 people at three diHerent plague prevalences (pretest probabilities): 0.1%, 4%, and 20%. We
selected prevalence values based on the range of prevalence observed across the included studies and on hypothetical field situations. We estimated confidence intervals based
on those around the point estimates for pooled sensitivity and specificity.
Abbreviations
CI: confidence interval; F1RDT: F1 antigen rapid diagnostic test.
Explanations
bDowngraded two levels for risk of bias: there is high risk of bias on the patient selection and flow and timing domains for all included studies (except Rajerison 2020, with low
risk of bias on flow and timing domain). The included studies were retrospective case series (except Chanteau 2003a, which was prospective with unclear sampling methods),
which was at high risk of introducing bias for evaluating diagnostic test accuracy.
cNot downgraded for inconsistency: there was an outlier corresponding to the pneumonic outbreak from 2017 to 2018 (Rajerison 2020), which includes four participants. The
remainder of findings showed consistency of sensitivity estimate towards 100%.
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dDowngraded two levels for imprecision: wide 95% CI around false negatives and false positives may lead to diHerent decisions depending on whether the upper or lower limit
is assumed.
eDowngraded one level for indirectness: there was high concern of applicability due to exclusion of people who received antibiotics prior to sample collection (Rajerison 2020).
This can lead to false-negative culture, which is the reference standard. In addition, the index test was performed in a central laboratory, which may not reflect the field conditions
in case of an outbreak.
GRADE certainty of evidence (GRADEpro GDT 2015)
High certainty: we are very confident that the true eHect lies close to that of the estimate of the eHect.
Moderate certainty: we are moderately confident in the eHect estimate: the true eHect is likely to be close to the estimate of the eHect, but there is a possibility that it is
substantially diHerent.
Low certainty: our confidence in the eHect estimate is limited: the true eHect may be substantially diHerent from the estimate of the eHect.
Very low certainty: we have very little confidence in the eHect estimate: the true eHect is likely to be substantially diHerent from the estimate of eHect.
 
 
Summary of findings 2.   F1RDT against culture for pneumonic plague
Review question: what is the diagnostic accuracy of F1RDT for the diagnosis of pneumonic plague in adults and children?
Setting: populations where plague has been known to occur and populations where an outbreak is in progress
Patient or population: adults and children with suspicion of pneumonic plague
Index test: F1RDT from Institut Pasteur of Madagascar performed in sputum
Reference standard: sputum culture
Study design: retrospective reports
Pooled sensitivity: 1.00 (95% CI 0.00 to 1.00). Pooled specificity: 0.71 (95% CI 0.59 to 0.80)
Number of results per 1000 participants tested (95% CI)aTest result
Prevalence 0.1% Prevalence 4% Prevalence 20%
Number
of par-
ticipants
(studies)
Certainty of
the evidence
(GRADE)
True positives (participants correctly classified as having pneumonic
plague)
1 (0 to 1) 40 (0 to 40) 200 (0 to 200)
False negatives (participants incorrectly classified as not having pneu-
monic plague)
0 (0 to 1) 0 (0 to 40) 0 (0 to 200)
56 (2) ⊕⊝⊝⊝
Very low b,c,d
True negatives (participants correctly classified as not having pneumonic
plague)
709 (589 to 799) 682 (566 to 768) 568 (472 to 640)
False positives (participants incorrectly classified as having pneumonic
plague)
290 (200 to 410) 278 (192 to 394) 232 (160 to 328)
297 (2) ⊕⊝⊝⊝
Very low b,d,e
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aThe table displays normalized frequencies within a hypothetical cohort of 1000 people at three diHerent pneumonic plague prevalences (pretest probabilities): 0.1%, 4%, and
20%. We selected prevalence values based on the range of prevalence observed across the included studies and on hypothetical field situations. We estimated confidence intervals
based on those around the point estimates for pooled sensitivity and specificity.
Abbreviations
CI: confidence interval; F1RDT: F1 antigen rapid diagnostic test.
Explanations
bDowngraded two levels for risk of bias: there was high or unclear risk of bias on the index test and flow and timing domains for both included studies. The design of both studies
was retrospective case series, which is at high risk of introducing bias for evaluating diagnostic test accuracy.
cNot downgraded for inconsistency: there was an outlier corresponding to the pneumonic outbreak from 2017 to 2018 (Rajerison 2020), which included four participants. The
remainder of the findings showed consistency of sensitivity estimate towards 100%.
dDowngraded two levels for imprecision: wide 95% CI around false negatives and false positives may lead to diHerent decisions depending on whether the upper or lower limit
is assumed. In addition, small number of participants included.
eDowngraded one level for indirectness: there was high concern of applicability due to exclusion of people who received antibiotics prior to sample collection. This can lead to
false-negative culture, which is the reference standard. In addition, the index test was performed in a central laboratory, which may not reflect the field conditions in case of
an outbreak.
GRADE certainty of evidence (GRADEpro GDT 2015)
High certainty: we are very confident that the true eHect lies close to that of the estimate of the eHect.
Moderate certainty: we are moderately confident in the eHect estimate: the true eHect is likely to be close to the estimate of the eHect, but there is a possibility that it is
substantially diHerent.
Low certainty: our confidence in the eHect estimate is limited: the true eHect may be substantially diHerent from the estimate of the eHect.
Very low certainty: we have very little confidence in the eHect estimate: the true eHect is likely to be substantially diHerent from the estimate of eHect.
 
 
Summary of findings 3.   F1RDT against culture for bubonic plague
Review question: what is the diagnostic accuracy of F1RDT for the diagnosis of bubonic plague in adults and children?
Setting: populations where plague has been known to occur and populations where an outbreak is in progress
Patient or population: adults and children with suspicion of bubonic plague
Index test: F1RDT from Institut Pasteur of Madagascar performed in bubo aspirate
Reference standard: culture from bubo aspirate
Study design: retrospective reports
Pooled sensitivity: 1.00 (95% CI not calculable). Pooled specificity: 0.67 (95% CI 0.65 to 0.70)
Number of results per 1000 participants tested
(95% CI)a
Test result
Prevalence
0.1%
Prevalence 4% Prevalence
50%
Number
of par-
ticipants
(studies)
Certain-
ty of the
evidence
(GRADE)
True positives (participants correctly classified as having bubonic plague) 1 40 500 1454 (2) ⊕⊕⊝⊝
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False negatives (participants incorrectly classified as not having bubonic plague) 0 0 0 Low 
b
True negatives (participants correctly classified as not having bubonic plague) 669 (649 to 699) 643 (624 to 672) 335 (325 to 350)
False positives (participants incorrectly classified as having bubonic plague) 330 (300 to 350) 317 (288 to 336) 165 (150 to 175)
1198 (2) ⊕⊝⊝⊝
Very low b,c
aThe table displays normalized frequencies within a hypothetical cohort of 1000 people at three diHerent bubonic plague prevalences (pretest probabilities): 0.1%, 4%, and 50%.
We selected prevalence values based on the range of prevalence observed across the included studies and on hypothetical field situations. We estimated confidence intervals
based on those around the point estimates for pooled sensitivity and specificity.
Abbreviations
CI: confidence interval; F1RDT: F1 antigen rapid diagnostic test.
Explanations
bDowngraded two levels for risk of bias: there was high risk of bias on the index test domain for both included studies. The design of both studies was retrospective, which is at
high risk of introducing bias for evaluating diagnostic test accuracy.
cDowngraded one level for indirectness on false-positive tests only. One of the included studies was at high concern of applicability due to exclusion of people who received
antibiotics prior to sample collection. This can lead to false-negative culture, which is the reference standard. In addition, the index test was performed in a central laboratory,
which may not reflect the field conditions in case of an outbreak.
GRADE certainty of evidence (GRADEpro GDT 2015)
High certainty: we are very confident that the true eHect lies close to that of the estimate of the eHect.
Moderate certainty: we are moderately confident in the eHect estimate: the true eHect is likely to be close to the estimate of the eHect, but there is a possibility that it is
substantially diHerent.
Low certainty: our confidence in the eHect estimate is limited: the true eHect may be substantially diHerent from the estimate of the eHect.
Very low certainty: we have very little confidence in the eHect estimate: the true eHect is likely to be substantially diHerent from the estimate of eHect.
 
 
Summary of findings 4.   F1RDT against PCR for bubonic plague
Review question: what is the diagnostic accuracy of F1RDT for the diagnosis of bubonic plague in adults and children?
Setting: populations where plague has been known to occur and populations where an outbreak is in progress
Patient or population: adults and children with suspicion of bubonic plague
Index test: F1RDT from Institut Pasteur of Madagascar performed in bubo aspirate
Reference standard: PCR (caf1) from bubo aspirate
Study design: retrospective reports
Pooled sensitivity: 0.95 (95% CI 0.89 to 0.99). Pooled specificity: 0.93 (95% CI 0.84 to 0.98)
Number of results per 1000 participants tested (95% CI)aTest result
Prevalence 0.1% Prevalence 4% Prevalence 50%
Number
of par-
ticipants
(studies)
Certainty of
the evidence
(GRADE)
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True positives (participants correctly classified as having bubonic
plague)
1 (1 to 1) 38 (36 to 40) 475 (445 to 495)
False negatives (participants incorrectly classified as not having bubonic
plague)
0 (0 to 0) 2 (0 to 4) 25 (5 to 55)
88 (1) ⊕⊝⊝⊝
Very low b,c
True negatives (participants correctly classified as not having bubonic
plague)
929 (839 to 979) 893 (806 to 941) 465 (420 to 490)
False positives (participants incorrectly classified as having bubonic
plague)
70 (20 to 160) 67 (19 to 154) 35 (10 to 80)
61 (1) ⊕⊝⊝⊝
Very low b,c
aThe table displays normalized frequencies within a hypothetical cohort of 1000 people at three diHerent bubonic plague prevalences (pretest probabilities): 0.1%, 4%, and 50%.
We selected prevalence values based on the range of prevalence observed across the included studies and on hypothetical field situations. We estimated confidence intervals
based on those around the point estimates for pooled sensitivity and specificity.
Abbreviations
CI: confidence interval; F1RDT: F1 antigen rapid diagnostic test; PCR: polymerase chain reaction.
Explanations
bDowngraded two levels for risk of bias: there was high risk of bias on the index test domain. The estimates were assessed by one retrospective study, which is a study design
at high risk of introducing bias for evaluating diagnostic test accuracy.
cDowngraded two levels for imprecision: wide 95% CI around false positives (and false negatives for high pretest probability of the disease) may lead to diHerent decisions
depending on whether the upper or lower limit is assumed. In addition, small number of participants included.
GRADE certainty of evidence (GRADEpro GDT 2015)
High certainty: we are very confident that the true eHect lies close to that of the estimate of the eHect.
Moderate certainty: we are moderately confident in the eHect estimate: the true eHect is likely to be close to the estimate of the eHect, but there is a possibility that it is
substantially diHerent.
Low certainty: our confidence in the eHect estimate is limited: the true eHect may be substantially diHerent from the estimate of the eHect.
Very low certainty: we have very little confidence in the eHect estimate: the true eHect is likely to be substantially diHerent from the estimate of eHect.
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
B A C K G R O U N D
Target condition being diagnosed
Plague has caused major historic pandemics including the 'Plague
of Justinian' in the 6th century, the 'Black Death' in the 14th
century (which resulted in the death of one-third of the European
population), and the 'Third Pandemic' in the 19th century
(Rasmussen 2015). This severe disease remains a current threat
in many parts of the world, and has increased over the last
three decades (WHO 2009). Between 1989 and 2003, 25 countries
reported 38,310 human cases of plague, including 2845 deaths
(WHO 2019a). Since 2000, over 95% of the burden associated with
plague has been concentrated in Africa, particularly the Democratic
Republic of the Congo (DRC), Madagascar, Uganda, and the United
Republic of Tanzania (WHO 2016; WHO 2019a). Peru and the USA
also regularly report cases. Finally, although Asia is the region with
the biggest natural foci of the disease, the reservoir consists of
gerbils and marmots; there is a limited at-risk population in contact
with these animals, so outbreaks are sporadic (WHO 2016). As of
2017, the DRC, Madagascar, and Peru had the highest incidence
of the disease. However, countries that have never experienced
plague, or not experienced plague for a long while, can be aHected
as the limits of the existing foci are not fixed and new foci can
emerge. Human plague outbreaks are continuously being reported,
from Indonesia in 2007 and the DRC and Tanzania in 2014, to
the outbreak of pneumonic plague more recently reported in
Madagascar in 2017 (WHO 2009; WHO 2016; WHO 2019a).
Plague is caused by the bacteria Yersinia pestis. It is primarily
a vector borne zoonotic disease, aHecting rodents and other
wild and domestic animals. It is most commonly transmitted to
humans by rodent fleas, leading to bubonic plague. Less frequently,
plague can be transmitted through scratches or bites from infected
animals, direct handling of infected animals, and human-to-human
transmission by inhalation of droplets from people with pneumonic
plague (CDC 2019; Weniger 1984).
Plague can aHect both adults and children, with no diHerences
between genders or ethnicities. However, the disease presents
more frequently among people involved in activities with an
increased exposure to the disease, such as hunters, veterinarians,
etc. Poverty is also associated with a greater risk of contracting
plague due to increased exposure to rodents.
Plague is always a medical emergency and presents in a variety
of forms, with three major clinical syndromes. Bubonic plague is
the most common form and is characterized by enlarged lymph
nodes with necrotic areas called buboes. Pneumonic plague is most
oOen a fulminant form which aHects the lungs and presents with
cough and bloody sputum. The pneumonic form can be primary
(as a result of inhalation of droplets from infected humans or
animals), or secondary (as a result of the haematogenous spread
of any other form of plague) (CIDRAP 2013). The third major clinical
form is septicaemic plague, which occurs when the infection
spreads to the circulatory system; it can be primary (without
buboes or pulmonary aHectation), or secondary (as a result of
spreading bubonic or pneumonic plague). Less commonly, plague
can present as meningitis (Prentice 2007).
Although eHicient antimicrobials are available, plague still has
a high mortality rate as most outbreaks take place in remote
places in resource-limited settings, where proper diagnosis and
treatment remains challenging (WHO 2009). While bubonic plague
is associated with case fatality ratios (CFRs) of 10% to 20%,
pneumonic plague is highly fatal, with a CFR close to 100%
if leO untreated and over 50% when adequately treated with
antimicrobials (Prentice 2007).
In addition to the sporadic cases and outbreaks, because of the
characteristics of the disease resulting in high mortality, Y pestis has
been used as a biological weapon and is currently a bioterrorism
threat (CDC 2019).
Due to its historical pandemics and high fatality rate, plague
continues to cause fear and panic, and is sometimes associated
with a disproportionate public health response, which has
considerable social and economic consequences (Mavalankar
1995; Mead 2018). A clinical diagnosis of plague is diHicult and
not reliable. The symptoms of pneumonic plague are not specific
and can be present in a person with pneumonia caused by
many other pathogens. These include other bacteria such as
streptococcus pneumoniae or tuberculosis, that would require
diHerent antibiotics than plague, but also viruses, such as influenza,
which would require no antibiotics. A person with a swollen lymph
node in an endemic area or in the context of an outbreak is
more likely to receive an accurate diagnosis of bubonic plague
than people with suspected pneumonic plague. However, other
diagnoses need to be considered, mainly other infections that
cause swollen lymph nodes such as pyogenic abscess, tularaemia,
tuberculosis, lymphogranuloma venereum, and cat scratch fever. A
point-of-care diagnostic tool that is quick to use and highly accurate
would help ensure appropriate response, especially in the context
of outbreaks.
Index test(s)
Rapid diagnostic tests (RDTs) detect pathogen-specific antigens
in a small quantity of diHerent body fluids through lateral flow
immunochromatography. RDTs are widely used in other diseases,
such as malaria (WHO 2019b). They are usually easy to use
and interpret. Indeed, they can be performed at the bedside
of the patient without the requirement of special equipment
or laboratory facilities. They give a simple result within around
15 minutes – positive or negative, at thresholds set by the
manufacturer – that can easily be interpreted by health workers
without advanced training. Therefore, RDTs are useful diagnostic
tools for use at the community level and in low-resource settings
(WHO 2019b).
In the case of plague, the RDT detects the F1 capsular antigen of Y
pestis (F1RDT), which is present in large amounts in buboes, blood,
and sputum from patients infected with plague. F1RDT is the only
RDT for plague that has been developed for clinical purposes that
we are aware of. The test gives a semi-quantitative result within
15 minutes according to the intensity of the line (from 1+ to 4+),
although it is most commonly used as a qualitative test (positive
or negative result) where positivity is interpreted from 1+ (as soon
as the line is visible). The threshold for positivity will depend on
the manufacturer, and is established by the lowest concentration
of the F1 antigen that the test can detect. The F1RDT can be used
in bubo aspirate, urine, and sputum (Chanteau 2000a); it is not
usually used in blood as the pink result line would be diHicult to
see. Currently, the F1RDT that is mainly used in the field is produced
in Madagascar. The most recent version was developed in 2001
(Chanteau 2003a). Other F1RDTs for plague are produced by New
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Horizons in the USA (New Horizons 2019) and in Taiwan (Hsu 2018),
but they are not licensed for use in humans or available in the
market.
Similar to other RDTs, F1RDT should be administered by trained
staH, following the manufacturer's restrictions and warnings of the
test. Although no advanced training is required, clear indications
must be respected. These include sample collection, sample
preparation, and timely and accurate reading of the result. Storage
conditions are indicated by each manufacturer and are usually easy
to comply with.
Clinical pathway
People of any age aHected by plague will present with non-specific
symptoms such as fever, chills, headache, or nausea; these are
usually associated with lymph node swelling in case of bubonic
plague, with or without cough, haemoptysis, and chest pain for
pneumonic plague. While a first diagnosis of suspected plague
is based on clinical findings, the definitive diagnosis requires
laboratory testing. Bacteriological identification of Y pestis through
microscopy or culture (or both) is the reference standard for a
confirmed case of plague (Rajerison 2020). Y pestis grows easily in
standard culture media, and, while bacteriological isolation has a
high specificity, it is also highly sensitive under ideal conditions.
However, administration of antibiotics prior to sample collection
is likely to lead to a false-negative result. Delay in transportation
from the time of collection to the central laboratory (which is not
uncommon in low-resource settings), associated or not with poor
storage conditions, can lead to decreased viability of the pathogen
and overgrowth of contaminating bacteria, with subsequent false-
negative results. Another confirmatory diagnosis of plague is
obtained by serology with a four-fold diHerence in F1 antibody
titres between paired serum samples, from acute and convalescent
phases. While this test is highly specific and allows diagnosis of
true cases of plague, a limitation in practice is the collection of the
second serum sample during the convalescence phase, as people
might return to their home or work setting as soon as they feel well
enough. Another technique more recently used in the diagnosis
of plague is polymerase chain reaction (PCR), targeting several
genes including the pla gene, encoding plasminogen activator, and
the caf1 gene, encoding F1 capsule antigen. This technique only
requires a small amount of sample, and detects specific genes
of Y pestis whether the bacteria is alive or dead. A person with
plague who has received antibiotics prior to sample collection
might present a negative culture (false negative) but a positive PCR.
These diagnostic tests (culture, paired serology, and PCR) require
technology and qualified staH, which are rarely available in
resource-limited areas. In addition, results from culture and paired
serology take several days. These tests do not allow a fast
confirmation or exclusion of plague diagnosis, and physicians
cannot rely on them for the acute management of patients.
Therefore, in practice, as soon as a case of plague is clinically
suspected in an area where plague is endemic (or if the case visited
an endemic area), the patient is immediately given antibiotics
following collection of biological samples (blood, sputum, bubo
aspirate, or a combination of these) whenever possible, and
managed as a case of plague until microbiological diagnosis is
confirmed or excluded, usually based on culture results. It is
common that patients finish the treatment course or evolve to
a fatal outcome before plague is microbiologically confirmed.
In addition, public health measures are established, especially
for cases of pneumonic plague, including tracing contacts and
distributing chemoprophylaxis.
The use of the F1RDT, performed for all suspected cases of plague
during the first contact of the patient with healthcare facilities,
would support the clinical suspicion of plague when positive,
and guide physicians to consider other diseases when negative,
providing valuable guidance for both clinical and public health
response.
Prior test
It is very unlikely that patients will have had another diagnostic
test for detecting plague prior to presentation to the health facility
where the F1RDT would be performed, as the F1RDT should be
performed at the first point of presentation with medical facilities.
Role of index test
The role of the F1RDT is to provide bedside rapid results in the
identification of people with plague, to allow prompt treatment,
and to establish preventive measures in order to limit transmission
of the disease to others in case of a positive result for pneumonic
plague. A negative F1RDT finding would prompt clinicians to
consider other diagnoses for correct management of the patient
and to avoid unnecessary preventive measures that would be
essential in case of plague. An easy-to-use and accurate F1RDT for
plague would, therefore, be of considerable help in daily clinical
practice for the management of people with suspicion of plague
in endemic areas by providing a fast diagnosis, as microbiological
confirmation of plague takes several days. The F1RDT would be
used in addition to the reference standard and would not replace
culture, which is fundamental for assessing circulating strains and
antibiotic resistance testing. According to the specificity of the test,
the F1RDT could be used as a triage tool, meaning that a negative
result would definitely exclude plague, and that other tests – such
as culture – would only be collected in cases with a positive result,
and managed accordingly.
The F1RDT cannot be used as a screening tool for plague in
asymptomatic people, for example asymptomatic people who have
been in contact with people with plague. Indeed, samples to
perform the test are mainly bubo aspirate (in case of suspicion of
bubonic plague) and sputum (in case of pneumonic plague) and
those samples would be non-existent in asymptomatic people.
Alternative test(s)
Direct enzyme-linked immunosorbent assay (ELISA) for detection
of the F1 antigen is another test used for the diagnosis of plague. It
requires equipment as well as trained personnel to perform it, and
it is not easily available in low-resource settings.
Rationale
Plague is a serious illness with high mortality and rapid
transmission from fleas or in between humans if control
measures are not immediately implemented. Given the non-
specific symptoms of plague and the measures to be implemented
in the event of a confirmed case (such as surveillance measures,
identification of contacts for prophylaxis, and safe burial to avoid
spread of the disease), it is crucial to make a formal diagnosis of
plague as soon as possible to distinguish it from other infections
with similar clinical presentation. This is particularly important for
the pneumonic form of plague, where the high prevalence of other
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infections presenting with similar respiratory symptoms such as
cough and fever makes an accurate clinical diagnosis diHicult. The
delay in a confirmed diagnosis may have two main repercussions.
The first is at the individual level, as confirmation or exclusion of the
diagnosis will help optimize the patient's management, including
consideration of alternative diseases and treatments. A confirmed
diagnosis allows targeted treatment with specific antibiotics. If
the diagnosis is not made, patients are likely to be treated with
routine empiric antibiotics which are ineHective against plague.
The second is at a public health level, as pneumonic plague can
be transmitted from human to human, leading to outbreaks, which
are oOen associated with fear, panic, and sometimes with excessive
measures that can lead to social and economic disruption, with
considerable consequences (Mavalankar 1995).
A highly accurate and fast diagnostic test would undoubtedly
be helpful. High accuracy of the test is imperative; indeed, low
sensitivity (i.e. high numbers of false negatives) would lead to
missed cases of plague in the situation where the test is used as
a screening tool (i.e. to exclude plague diagnosis when a negative
result is observed and pursue with microbiological analysis when
a positive result is observed), and to initial mismanagement of the
case until it is confirmed microbiologically. Low specificity would
probably lead to a bigger concern. A false-positive case might
trigger unnecessary social alert, avoidable anxiety to the patients
and their family, and avoidable use of resources, particularly
in fragile health systems in countries where plague is endemic
(Mavalankar 1995; Mead 2018). A highly specific test with a very low
false-positivity rate would allow the adequate management of all
negative cases, considering them true-negative cases.
Another important consideration to consider while evaluating the
F1RDT is the use and importance of specificity of the test in
diagnosing people with suspicion of pneumonic plague in the
context of an outbreak. The pneumonic form of plague is a very
severe and fatal disease that can be transmitted from human
to human. Contrary to the bubonic form, where the presence
of buboes might facilitate the suspicion of plague, symptoms
presented with the pneumonic plague are less specific. In addition,
the obtention of a good sample to run the F1RDT might be more
diHicult in the pneumonic plague, where it might be challenging
to obtain good-quality sputum from children and from severely ill
people with decreased consciousness. Performing the test in saliva
instead of sputum will certainly lead to diHerent accuracy findings,
and this should be taken into account.
The F1RDT is a simple diagnostic tool that can be performed at
the bedside of the patient, with a fast result that allows prompt
diagnosis and early treatment, as well as timely implementation of
control measures to limit the spread of the disease. Therefore, the
F1RDT has the potential to be useful to health workers, and could
contribute to reducing the high mortality attributed to plague, as
well as inadequate public health responses to it. However, there
is no systematic review assessing the diagnostic test accuracy of
the F1RDT for plague against standard diagnostic tests. Currently,
a confirmed case of plague is made either by isolation of Y pestis
(culture) or by acute and convalescent serological antibody testing
(four-fold diHerence in F1 antibody titres), according to World
Health Organization (WHO) definitions (WHO 2019a). Positivity of
either test provides a reliable diagnosis of plague and can be used
interchangeably to consider a case of plague (although culture is
preferred in order to identify the strain and resistance pattern).
Therefore, it is reasonable to assess the accuracy of the F1RDT
against both these tests. With the increasing inclusion of molecular
biology for the diagnosis of many infectious diseases, we thought
it was relevant to also assess accuracy of the F1RDT against PCR.
However, to date, there is a lack of evidence supporting the
superiority of one reference test above another.
The findings of this review will help to develop evidence-based
recommendations on the role of the F1RDT in the diagnosis
of plague, which could be included in clinical guidelines about
the management of plague as well as in guidelines on infection
prevention and control.
O B J E C T I V E S
To determine the diagnostic accuracy of the rapid diagnostic test
(RDT) based on the antigen F1 (F1RDT) for detecting plague in
people with suspected disease.
Secondary objectives
To assess the eHect of forms of plague (bubonic, septicaemic, or
pneumonic), specimen tested (bubonic aspirate, urine, or sputum),
prior antibiotic treatment, location where the test is performed
(field or laboratory studies), and threshold for detecting the disease
(as set by the manufacturer) on the accuracy of the F1RDT for
detecting the disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional studies that assess the accuracy of the
F1RDT for diagnosing plague in the laboratory or in field conditions,
where patients were tested for plague with both the F1RDT and at
least one of the reference standards (culture, PCR, or serology). We
excluded case-control (two-gate cross-sectional) studies as we aim
to determine accuracy of the RDT from only one set of participants,
all of them with suspected plague.
Participants
We included participants (including children and pregnant women)
living in or visiting areas where plague was endemic, who presented
to any healthcare facility (primary, secondary, or tertiary care) with
clinical suspicion of any form of plague. For studies where only a
subgroup of participants was eligible for inclusion in the review,
we included the study when there were disaggregated data that we
could extract for that subgroup.
Index tests
The index test we assessed was the F1RDT performed in any
relevant sample to detect plague, this was bubo aspirate to detect
bubonic plague, sputum to detect pneumonic plague, and other
samples such as urine to detect septicaemic plague.
Target conditions
The target condition was any form of symptomatic plague
(bubonic, septicaemic, or pneumonic).
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Reference standards
We included studies that used one of the following reference
standards to diagnose plague.
• Isolation of Y pestis by culture.• PCR.• Serology showing a four-fold diHerence in F1 antibody titres
between two paired samples.
Search methods for identification of studies
We conducted the literature search up to 15 May 2019 (27 August
2019 for PubMed), and identified potential studies regardless of
language, publication status, or publication date.
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Central Register
of Controlled Trials (CENTRAL, published in the Cochrane Library,
Issue 5, May 2019), MEDLINE (PubMed, from 1966 to 27 August
2019), Embase (Ovid; from 1949 to 15 May 2019), Science Citation
Index (Web of Science, from 1900 to 15 May 2019). On 15 May
2019, we also searched Google Scholar (scholar.google.co.uk), and
the WHO International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp/en/), and ClinicalTrials.gov for trials in progress.
Searching other resources
We searched the proceedings and abstracts of relevant conferences
from the past five years: the International Symposium on Yersinia,
the American Society of Tropical Medicine and Hygiene conference,
and the congress of European Microbiologists. We handsearched
the reference lists of relevant papers and contacted researchers
working in the field. We also searched for related articles to the
included studies using the PubMed "similar articles" function, on
27 August 2019.
Data collection and analysis
Selection of studies
Two review authors independently screened all the abstracts
retrieved by the search strategy, using the predefined eligibility
criteria. We excluded studies that were clearly irrelevant based
on the titles and abstracts. We retrieved full-text copies of the
remaining studies and applied the predefined criteria for inclusion
in the review. We resolved any disagreements in assessment
through discussion. We listed all studies excluded aOer full-text
assessment in the Characteristics of excluded studies table. We
illustrated the study selection process in a PRISMA diagram (Figure
1).
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Figure 1.   Study flow diagram.
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Data extraction and management
One review author piloted the data extraction form on two studies.
Based on the results of the pilot, we modified and finalized
the data extraction form. Two review authors independently
conducted data extraction and management, using the finalized
data extraction form. We compared these data and resolved any
disagreement through discussion. For each included study, we
gathered information on the following (Appendix 2).
• Setting, design, and duration of the study.• Baseline characteristics of the study population and sample size.• Target condition: forms of plague assessed.• Index test used: name, detection target, need for sample
preparation, personnel who conducted the test, training
provided to personnel for conducting the test, location where
test performed.• Reference standard: test performed, personnel who conducted
the test, training provided to personnel for conducting the
test, location where test performed, conditions of storage, and
transport.• Results for both index and reference standard tests: missing
cases, uninterpretable results, true and false positives, true and
false negatives, sensitivity and specificity of index tests.• Other relevant details such as source of funding.
Assessment of methodological quality
Two review authors independently assessed the methodological
quality of each included study, using the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool, which is based on
four domains: participant selection, index test, reference standard,
and flow and timing (Whiting 2011). We have tailored the tool
to the context of this review (Appendix 3). We answered each of
the signalling questions as 'yes,' 'no,' or 'unclear,' and gave the
reason for our judgement. We resolved any disagreements through
discussion and through consultation with a third review author in
case of persisting disagreement.
Statistical analysis and data synthesis
We stratified all analyses by the reference standard used. Within
each stratum, we constructed a two-by-two table (containing the
number of true-positive, true-negative, false-positive, and false-
negative results) for each study. We entered the two-by-two data
into Review Manager 5 (Review Manager 2014). We summarized
estimates of sensitivity and specificity from each individual study
on forest plots and plotted the estimates using summary receiver
operating characteristic (SROC) plots.
We calculated positive (PPV) and negative predictive value (NPV)
estimates for various scenarios to help interpret the impact of
F1RDT findings. There are no data reporting estimates of pretest
probability of plague for the diHerent case scenarios. Therefore, we
estimated three case scenarios for each form of plague (bubonic
and pneumonic plague), to the best of our knowledge and in
consultation with experts in the field. The prevalence of 4% was
calculated based on the number of confirmed cases of plague
among notified cases of plague during the 2017 outbreak in
Madagascar, as a starting point. We estimated a lower pretest
probability of the disease at 0.1% for the context where plague was
known to occur but where there was no declared ongoing outbreak.
Finally, we estimated a higher pretest probability of the test, where
the test was used in the context of a declared outbreak. In the
case of bubonic plague in a context of known outbreak, a person
presenting with a bubo has high probability of having the disease.
Therefore, we estimated a high pretest probability of 50%. In the
case of pneumonic plague, the diHerential diagnosis is broader
than for bubonic plague, including other respiratory infections that
are highly prevalent. Therefore, we estimated a pretest probability
lower than for the case of bubonic plague, at 20%.
When meta-analysis was appropriate (given the number of studies
and extent of clinical heterogeneity), we pooled results from
the included studies. We used the bivariate model to obtain
pooled estimates of sensitivity and specificity, as meta-analysis
was performed for a single threshold. If data were sparse and
the bivariate model would not converge, we pooled data using
methods described by Takwoingi and colleagues (Takwoingi 2017).
All meta-analyses were performed using the xtmelogit commands
in Stata version 14 (Stata 2015). We plotted the pooled estimates
of sensitivity and specificity using SROC plots in Review Manager 5
(Review Manager 2014).
Investigations of heterogeneity
We stratified the findings by type of reference standard used:
bacterial isolation by culture, PCR, and serology showing a four-
fold diHerence in F1 antibody titres between two samples from
acute and convalescent phases. For PCR, we described all the genes
that the included studies assessed. However, when we needed to
choose one gene (i.e. for meta-analysis), we used caf1, which is the
most relevant gene as according to experts in the field.
We planned to assess the impact of forms of plague on the accuracy
of F1RDT by performing meta-regression. However, there were an
insuHicient number of studies to obtain reliable results from meta-
regression. We instead presented the findings stratified by forms of
plague, as this is clinically relevant.
We also planned to assess the impact of prior antibiotic treatment,
location of performance of the F1RDT (field and central laboratory),
and threshold for detecting the disease on accuracy of F1RDTs
by performing subgroup analyses or meta-regression. It was not
possible to assess the impact of prior antibiotic treatment or
location of performance of the F1RDT test due to scarcity of the
data. Furthermore, it was not necessary to assess the impact of
threshold as studies were consistent with regards to the threshold
used to determine disease status.
Sensitivity analyses
We planned to perform a sensitivity analysis in which we only
included studies that had a low risk of bias for the four domains
(patient selection, index test, reference standard, and flow and
timing), or restricted to those studies at low risk of bias for
patient selection only. However, it was not possible to perform this
sensitivity analysis as none of the included studies were at low risk
of bias for the patient selection domain.
Two manuscripts analyzed two cohorts with overlap of participants
(Andrianaivoarimanana 2019; Rajerison 2020). We included
Rajerison 2020 in the primary analysis and performed a
sensitivity analysis in which we repeated the analysis including
Andrianaivoarimanana 2019.
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We identified an outlier in the primary analysis assessing RDT
against culture for all forms of plague. We performed a sensitivity
analysis to explore the impact of this outlier in the pooled estimate.
Assessment of reporting bias
Little is known on how to assess and detect reporting bias for
diagnostic test accuracy studies (Macaskill 2010). We decided not
to carry out a formal assessment of publication bias using methods
such as funnel plots or regression tests because such techniques
have important limitations when used in reviews of diagnostic test
accuracy.
Assessment of the certainty of the evidence
We assessed the certainty of the evidence using GRADE and
GRADEpro GDT soOware (GRADE Handbook 2013; GRADEpro GDT
2015; Schünemann 2020). We rated the certainty of the evidence as
high, moderate, low, or very low by assessing four domains (risk of
bias, indirectness, inconsistency, and imprecision), as follows.
• Risk of bias: we assessed risk of bias by using the QUADAS-2 tool.• Indirectness: we used the QUADAS-2 tool to assess applicability
concerns and looked for important diHerences between the
populations studied, the setting, and the review question.• Inconsistency: we explored inconsistency by investigating
potential sources of heterogeneity, and we downgraded
the certainty of the evidence when we could not explain
inconsistency in the accuracy estimates.• Imprecision: we considered the width of the confidence intervals
(CIs) and questioned whether the truth set at the lower or
upper limit of the 95% CI would change our decision. We
calculated absolute numbers of true positives, true negatives,
false positives, and false negatives, with ranges for these values
based on the CIs of the pooled estimates of sensitivity and
specificity for various prevalences of plague, and we made
judgements on imprecision using these calculations.
We constructed 'Summary of findings' tables, which showed the
main review findings along with the certainty of the evidence.
R E S U L T S
Results of the search
The search identified 727 records. We identified six additional
papers by handsearching or by contacting experts. AOer excluding
duplicates and manuscripts published before 1995 (before which
F1RDT was not available), we selected 623 records for screening.
We excluded 580 of them based on title and abstract. Among the
43 publications identified for full-text review, we could not retrieve
the full-text of one of them. We assessed the full-text of 42 articles
and excluded 34 of them, with the reasons for exclusion listed in the
Characteristics of excluded studies table. See Figure 1 for the flow
diagram of the study selection process.
Eight manuscripts met our inclusion criteria. Two manuscripts
from Bertherat and colleagues reported the same plague outbreak
that occurred in the DRC in 2005. As the manuscript published
in 2005 did not provide additional data to the manuscript
published in 2011, we merged the documents and referred
to them in this review under one study ID (Bertherat 2011).
Andrianaivoarimanana 2019 and Rajerison 2020 presented data on
plague in Madagascar from national surveillance records, with an
overlap of participants between the two manuscripts for the period
between 2002 and 2007. We described the manuscripts separately
in the Characteristics of included studies tables as they applied
diHerent exclusion criteria to the cohort of participants. However,
we chose to include Rajerison 2020 in the primary analysis, as
Rajerison 2020 presented additional data for two outbreaks with
disaggregated data for bubonic and pneumonic plague.
We described the seven studies in the Characteristics of included
studies table and their key findings in Table 1. Five studies reported
findings of F1RDT used in plague epidemics in Madagascar between
2000 and 2019 (Andrianaivoarimanana 2019; Chanteau 2003a;
Rajerison 2020; Richard 2015; Riehm 2011). One study assessed
data from two outbreaks that occurred in the DRC in 2005 and 2006
(Bertherat 2011), and one study described performance of F1RDT
from several clinics both in Madagascar and Uganda, from 2004 to
2017 (Petersen 2018).
The studies included in the primary analyses reported data from
4146 participants (Andrianaivoarimanana 2019 excluded) including
adults and children of both sex. Among them, 3989 samples were
analyzed with both the index test and at least one reference
standard.
One study assessed only bubonic plague (Riehm 2011), two
studies assessed only pneumonic plague (Bertherat 2011;
Richard 2015), and four studies assessed all forms of plague
(Andrianaivoarimanana 2019; Chanteau 2003a; Petersen 2018;
Rajerison 2020). Samples used to perform F1RDT were bubo
aspirates in participants with suspicion of bubonic plague and
sputum in participants with suspicion of pneumonic plague (this
was also assumed for Andrianaivoarimanana 2019 but was not
clearly reported). F1RDT was also performed in a few postmortem
tissue samples in two studies (Chanteau 2003a; Rajerison 2020).
The postmortem tissue samples were not relevant to this review
question; however, disaggregated data were not available, so we
could not exclude them from our analysis. Rajerison 2020 excluded
cases for which time of transport of the biological samples from
collection to the laboratory was superior to seven days and cases
who received antibiotics prior to sample collection.
The studies used two diHerent F1RDT dipsticks. All studies except
one (Petersen 2018) used the F1RDT produced at the Institut
Pasteur of Madagascar (F1RDT-IPM), which is based on the
combination of two anti-F1 antibodies (B18–1 and G6–18), with a
lower detection threshold of the F1 antigen of 0.5 ng/mL. Petersen
2018 assessed a F1RDT from New Horizons (F1RDT-NH), utilized by
the US Centers for Disease Control and Prevention (CDC), with a
lower detection threshold of the F1 antigen of 1 ng/mL (personal
communication). Additional and extensive data on performance of
this test are due to be published. According to the manufacturers,
both F1RDT-IPM and F1RDT-NH can be stored at room temperature.
Three studies performed F1RDT in a central laboratory (Chanteau
2003a; Petersen 2018; Rajerison 2020), and two studies both on site
and in a central laboratory (Bertherat 2011; Riehm 2011). It was
also performed on site in Chanteau 2003a, but data included for
analysis were based from the findings of those performed in the
central laboratory. It was unclear where the test was performed
in Richard 2015. Andrianaivoarimanana 2019 did not report the
location of performance of F1RDT, but we deduced it was in a
central laboratory, as there was an overlap of participants from
Rajerison 2020. The people who performed the F1RDT were a
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trained biologist in Bertherat 2011, and trained doctors, nurses,
and health workers in Chanteau 2003a. Such information was not
reported for the remaining studies.
All studies compared F1RDT against culture, three studies against
PCR (Bertherat 2011; Richard 2015; Riehm 2011), and two studies
against paired serology (Petersen 2018; Richard 2015).
The Institut Pasteur of Madagascar, which produced one of the
two dipsticks assessed in this review, supported two studies
(Chanteau 2003a; Richard 2015). Other financial support or
sponsors were the Institut Pasteur of Paris (Chanteau 2003a), the
WHO (Rajerison 2020), and the President's Malaria Initiative/US
Agency for International Development and the US Department of
Homeland Security (Richard 2015). Four studies did not report the
source of funding (Andrianaivoarimanana 2019; Bertherat 2011;
Petersen 2018; Riehm 2011).
Methodological quality of included studies
See the Characteristics of included studies table for the assessment
of the methodological quality of each included manuscript, and
Figure 2 for risk of bias and applicability concerns summaries.
 
Figure 2.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study.
 
In the patient selection domain, we considered all studies except
one (Petersen 2018) at high risk of bias, because recruitment of
participants was not consecutive or random but based on selection
of participants based on clinicians who declared cases to the
national surveillance system, following a retrospective design; in
addition, there were unclear exclusion criteria. In some studies,
administration of antibiotics prior to sample collection was not
taken into account, which could have led to a false-negative
culture when the participant truly had plague, and therefore
misclassification of the test to detect the disease. We considered
Petersen 2018 at unclear risk of bias as there were insuHicient data
to judge on this domain. Regarding applicability, five studies had
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low concern in the patient selection domain because the studies
included the appropriate participants and settings (outbreak and
national surveillance in endemic areas). Two studies were at
unclear concern because there were insuHicient data from Petersen
2018, and because there were limited information from the only
two participants in Richard 2015.
In the index test domain, we judged two studies at low risk of
bias because the F1RDT was interpreted without the knowledge
of the results of the reference standard, and we considered them
to have low concern for applicability (Bertherat 2011; Chanteau
2003a). The other five studies were at unclear risk of bias because
we do not know if the result of the F1RDT was interpreted without
the knowledge of the results of the reference standard. In addition,
these studies did not report the way that the test was conducted,
such as who performed the test, where it was performed, or the
need for sample preparation. We therefore considered the conduct
and interpretation of the index test to be of unclear concern for
applicability in these five studies (Andrianaivoarimanana 2019;
Petersen 2018; Rajerison 2020; Richard 2015; Riehm 2011).
In the reference standard domain, we considered all studies at
low risk of bias, as they all used culture, and four studies also
used PCR, paired serology, or both, which correctly classify the
target condition. For most studies, it was unclear whether the
interpretation of the reference standard was blinded to the RDT
result, but reference standard results are objective findings and
we considered this to be at low risk to introduce bias, and at low
concern of applicability.
In the flow and timing domain, we considered three studies at
high risk of bias because the time of sample transportation was
longer than seven days, which can lead to decreased viability
of the pathogen and overgrowth of contaminating bacteria, with
subsequent false-negative results and misclassification of the
target condition (Bertherat 2011; Chanteau 2003a; Riehm 2011). In
addition, in one study, all participants did not receive the same
reference standard (Bertherat 2011). We considered one study
at low risk of bias in this domain as they excluded participants
who received antibiotics prior to enrolment and those for whom
samples took longer than seven days to reach the central laboratory
(Rajerison 2020). This was unclear for the remaining three studies.
Findings
We present the findings for all forms of plague, and then present
findings disaggregated for pneumonic and bubonic plague. We
could not pool the findings from the two diHerent F1RDT used
(F1RDT-IPM and F1RDT-NH) as the tests present diHerent lower
detection thresholds for considering the test positive. Furthermore,
the only study that assessed the F1RDT-NH used combined
reference standards to consider true cases of plague (Petersen
2018).
We present the summary of findings including true positive, false
positive, false negative, true negative, sensitivity, and specificity for
each study with disaggregated data on F1RDT for diagnosing the
diHerent forms of plague against the diHerent reference standard in
Table 2.
1. F1RDT for diagnosing all forms of plague
a. F1RDT from Institut Pasteur of Madagascar
F1RDT-IPM versus culture for diagnosing all forms of plague
Six studies reported data on F1RDT-IPM and culture findings
for diagnosing all forms of plague. We used Rajerison 2020 in
our primary analysis and performed sensitivity analysis with
Andrianaivoarimanana 2019.
Primary analysis
Sensitivity estimates ranged from 25% to 100% and specificity
estimates ranged from 51% to 82% (Table 2).
Two data set were not included in the meta-analysis; Richard
2015 reported zero true-positive and zero true-negative cases and,
therefore, had no estimable sensitivity or specificity, and Bertherat
2011 reported a true-positive value of zero for the 2005 outbreak
and, therefore, had no estimable sensitivity.
Four studies contributed to the final primary meta-analysis
(Bertherat 2011 (2006 outbreak only); Chanteau 2003a; Rajerison
2020; Riehm 2011) (Figure 3). For the diagnosis of all forms of
plague, F1RDT-IPM pooled sensitivity against culture was 100%
(95% CI 82 to 100; 4 studies, 1692 participants; very low-certainty
evidence) and specificity was 70% (95% CI 65 to 75; 4 studies, 2004
participants; very low-certainty evidence) (Summary of findings 1)
(Figure 4). These results were from two univariate random-eHects
meta-analyses, one for sensitivity and one for specificity.
 
Figure 3.   Forest plot of 1 F1 antigen rapid diagnostic test (F1RDT) versus culture for all forms of plague, primary
analysis. The data for Bertherat 2011 refer to the 2006 outbreak only. CI: confidence interval; FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
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Figure 4.   Summary receiver operating characteristic (SROC) plot of one F1 antigen rapid diagnostic test (F1RDT)
versus culture for all forms of plague, primary analysis. Pooled sensitivity: 100% (95% CI 82 to 100); pooled
specificity: 70% (95% CI 65 to 75). The solid black dot corresponds to the pooled estimate of sensitivity and
specificity; the black circles show individual study results and their size corresponds to the sample size of the study
contributing to the analysis.
 
By considering the forest plot, we found that sensitivity from
participants with pneumonic plague in the 2017 to 2018 period
reported by Rajerison 2020 were not in line with the rest of the
sensitivity estimates by the other studies. There was a limited
number of four cases in this period, all four had positive culture but
only one had a positive RDT. This could have been due to several
factors such as the quality of sputum samples. We decided to keep
this outlier in the meta-analysis as it did not reflect any situation
inherently diHerent from the other studies.
Out of the 691 biological samples evaluated by Chanteau 2003a,
RDT was performed on 35 postmortem samples from lung or liver
puncture. The authors did not present disaggregated data for those
samples or by forms of plague. As these samples constituted 5% of
the overall samples evaluated in this study, we decided to include
these findings.
We did not investigate whether type of plague explained
heterogeneity by introducing a covariate to the bivariate model,
as there were an insuHicient number of studies to produce
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reliable results. However, we did produce an SROC plot which
allowed visual examination of how sensitivity and specificity varied
between subgroups (Figure 5). There was no clear pattern within
the limited number of studies to suggest that diHerences existed
between the diHerent forms of plague.
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Figure 5.   Summary receiver operating characteristic (SROC) plot of one F1 antigen rapid diagnostic test (F1RDT)
versus culture for all forms of plague, primary analysis, for investigation of heterogeneity. Each circle (all forms of
plague with no disaggregated data), square (pneumonic plague), and diamond (bubonic plague) corresponds to
individual study results. Their size corresponds to the sample size that contributed to the estimate of sensitivity and
specificity.
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Sensitivity analyses
We performed sensitivity analysis by excluding Rajerison 2020
and including Andrianaivoarimanana 2019. Both studies were
conducted from surveillance data in Madagascar, but Rajerison
2020 presented disaggregated data for participants with bubonic
and pneumonic forms of plague for three diHerent times (2002 to
2007, 2017 to 2018, and 2018 to 2019), and Andrianaivoarimanana
2019 presented sensitivity and specificity estimates from all forms
of plague during the 2002 to 2007 period. In addition, and contrary
to Andrianaivoarimanana 2019, Rajerison 2020 excluded from
analysis cases for which time of transport of biological samples was
more than seven days, and cases who received antibiotics prior to
sample collection, which would ensure a better performance of the
standard test for comparison.
We found very similar findings to the primary analysis, with a
pooled sensitivity of 100% (95% CI 70 to 100) and pooled specificity
of 71% (95% CI 65 to 77) (Figure 6). These results were from two
univariate random-eHects meta-analyses, one for sensitivity and
one for specificity.
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Figure 6.   Summary receiver operating characteristic (SROC) plot of 2 F1 antigen rapid diagnostic test (F1RDT)
versus culture for all forms of plague, sensitivity analysis. Pooled sensitivity: 100% (95% CI 70 to 100); pooled
specificity: 71% (95% CI 65 to 77). The solid black dot corresponds to the pooled estimate of sensitivity and
specificity; the black circles show individual study results and their size corresponds to the sample size of the study
contributing to the analysis.
 
We also performed sensitivity analysis by excluding the data on
pneumonic plague from Rajerison 2020 for the 2017 to 2018 period,
identified as an outlier. Although the CI for sensitivity was wider,
we found no diHerence to the pooled results as compared with the
primary analysis (pooled sensitivity of 100%, 95% CI 49 to 100 and
pooled specificity of 70%, 95% CI 65 to 74). These results were from
one bivariate random-eHects meta-analysis,
F1RDT-IPM versus PCR for diagnosing all forms of plague
Three studies provided data on both F1RDT-IPM and PCR findings
(Bertherat 2011, 2005 outbreak; Richard 2015; Riehm 2011). We
summarized the outcomes in Table 2. Sensitivity estimates ranged
from 72% to 95% and specificity estimates ranged from 50% to 93%.
The specificity estimate of 50% was based from a sample size of two
participants (Bertherat 2011, 2005 outbreak).
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Riehm 2011 assessed the performance of three diHerent genes by
PCR in the same set of 149 participants. We calculated a sensitivity
of 95% and specificity of 93% for the caf1 gene, 72% and 93% for
the pla gene, and 92% and 87% for the Ymt gene.
Bertherat 2011 (2005 outbreak) and Richard 2015 provided data on
two participants each. It was not possible to estimate sensitivity in
Bertherat 2011 (2005 outbreak) as the reference standard identified
no cases of plague, and it was not possible to assess specificity
in Richard 2015 as the reference standard only identified cases
of plague. With one study remaining (Riehm 2011), we could not
perform meta-analysis to assess the performance of F1RDT-IPM
versus PCR.
F1RDT-IPM versus paired serology for diagnosing all forms of
plague
Only one study reported data with F1RDT-IPM and paired serology
findings (Richard 2015). Both tests (F1RDT-IPM and paired serology)
were performed on sputum in two participants, and were positive
in both participants (Table 2).
b. F1RDT from New Horizons
One study reported findings of the F1RDT-NH for diagnosing plague
(Petersen 2018).
Confirmed cases of plague were defined as isolation of Y pestis by
culture in bubo, blood, or sputum, or 4-fold change in titre between
acute and convalescent serum samples. Participants confirmed
as non-plague were defined as Y pestis not isolated from culture
and no significant change in titre between acute and convalescent
serum samples.
From the limited available data, there were 118 confirmed cases of
plague (34 from Madagascar and 84 from Uganda); among which
109 where cases of bubonic plague. There were 136 participants
tested and confirmed as non-plague (61 from Madagascar and 75
from Uganda), among which 116 were suspected bubonic plague.
F1RDT-NH gives a semi-quantitative result according to the
intensity of the line in the dipstick, from 1+ to 4+. Where positivity
of F1RDT-NH was interpreted from 1+ (this is as soon as the line is
visible), the test presented a sensitivity of 90.6% (95% CI 83.8 to
95.2) and a specificity of 88.0% (95% CI 82.9 to 93.3), as reported
by the study authors. When evaluating F1RDT-NH with positivity
results from 2+, the test presented a sensitivity of 87.4% (95% CI
80.1 to 93.0) and a specificity of 97.7% (95% CI 93.4 to 99.5).
Comprehensive findings of this F1RDT-NH should be published
soon (personal communication).
2. F1RDT for diagnosing pneumonic plague
a. F1RDT from Institut Pasteur of Madagascar
F1RDT-IPM versus culture for diagnosing pneumonic plague
Three studies provided findings from both F1RDT-IPM and culture
for diagnosing pneumonic plague (Bertherat 2011; Rajerison 2020;
Richard 2015) (Table 2). Sensitivity was 100% with broad 95% CI
(the lowest lower limit was 40%), except for the 2017 to 2018 period
reported by Rajerison 2020 that showed a sensitivity of 25% (Figure
7). There was a limited number of four cases during this period,
which had positive culture but only one of them had a positive
RDT. This could be due to several factors such as technical issues in
preparing the sputum sample for analysis or in running the F1RDT.
Specificity estimates ranged from 51% to 82%.
 
Figure 7.   Forest plot of 1 F1RDT versus culture for pneumonic plague. CI: confidence interval; FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
 
Only two studies provided data that allowed estimation of both
sensitivity and specificity of the test (Bertherat 2011; Rajerison
2020), and so these two studies contributed to the meta-analysis.
Performed in sputum, F1RDT-IPM pooled sensitivity against culture
was 100% (95% CI 0 to 100; 2 studies, 56 participants; very low-
certainty evidence) and pooled specificity was 71% (95% CI 59 to
80; 2 studies, 297 participants) (Summary of findings 2) (Figure
8). These results were from one bivariate random-eHects meta-
analysis.
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Figure 8.   Summary receiver operating characteristic (SROC) plot of 1 F1 antigen rapid diagnostic test (F1RDT)
versus culture for pneumonic plague. Pooled sensitivity: 100% (95% CI 0 to 100); pooled specificity: 71% (95% CI 59
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to 80). The solid black dot corresponds to the pooled estimate of sensitivity and specificity; the black circles show
individual study results and their size corresponds to the sample size of the study contributing to the analysis.
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F1RDT-IPM versus PCR for diagnosing pneumonic plague
Bertherat 2011 (2005 outbreak) and Richard 2015 provided findings
of the F1RDT-IPM for diagnosing pneumonic plague. However, it
was not possible to assess sensitivity in Bertherat 2011 (2005
outbreak) as there were no cases of plague identified by PCR
(sensitivity cannot be calculated when there are no cases identified
as this would involve dividing by zero), and it was not possible
to assess specificity in Richard 2015 as PCR only identified cases
of plague (specificity cannot be calculated when only cases are
identified as this would involve dividing by zero). Therefore, we did
not pool data from these two studies in a meta-analysis.
F1RDT-IPM versus paired serology for diagnosing pneumonic
plague
Richard 2015 provided findings of the F1RDT-IPM for diagnosing
two participants with pneumonic plague, but it was not possible
to assess specificity as the paired serology only identified cases of
plague.
b. F1RDT from New Horizons
There were no disaggregated findings for pneumonic plague from
the F1RDT-NH test.
3. F1RDT for diagnosing bubonic plague
There was no disaggregated findings for bubonic plague from the
New Horizons test. The findings below are from studies assessing
the F1RDT-IPM.
a. F1RDT from Institut Pasteur of Madagascar
F1RDT-IPM versus culture for diagnosing bubonic plague
Two studies performed both the F1RDT-IPM and culture in
participants with suspicion of bubonic plague (Rajerison 2020;
Riehm 2011) (Table 2). Sensitivity estimates were 100% for all the
time periods presented by the two studies, thereby it was not
possible to pool data for sensitivity estimates (Figure 9). Specificity
estimates ranged from 60% to 82%. F1RDT-IPM performed in bubo
aspirate for diagnosing bubonic plague showed a pooled specificity
of 67% (95% CI 65 to 70; 2 studies; 1198 participants).
 
Figure 9.   Forest plot of 1 F1RDT versus culture for bubonic plague. CI: confidence interval; FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
 
F1RDT-IPM versus PCR for diagnosing bubonic plague
One study assessed the performance of three diHerent genes by
PCR in the same set of 149 participants (Riehm 2011). We calculated
the sensitivity and specificity of the F1RDT-IPM against each of
these genes, and found sensitivity of 95% (95% CI 89 to 99) and
specificity of 93% (95% CI 84 to 98) for the caf1 gene, 72% (95% CI
63 to 80) and 93% (95% CI 77 to 99) for the pla gene, and 92% (95%
CI 84 to 97) and 87% (95% CI 76 to 94) for the Ymt gene (Table 2).
F1RDT-IPM versus paired serology for diagnosing bubonic
plague
We found no studies assessing the accuracy of F1RDT-IPM against
paired serology for the diagnosis of bubonic plague.
b. F1RDT from New Horizons
There were no disaggregated findings for bubonic plague from the
F1RDT-NH test.
D I S C U S S I O N
Summary of main results
This systematic review of the diagnostic accuracy of F1RDT for
diagnosing any form of plague in people with suspected disease
summarizes the current literature and includes seven studies
described in eight manuscripts. Three studies described the
performance of F1RDT for diagnosing pneumonic plague and two
studies for diagnosing bubonic plague, with no disaggregated data
for forms of plague in three studies. The evidence came from three
African countries (Madagascar, the DRC, and Uganda) with findings
of F1RDT used during outbreaks or surveillance system in settings
where plague is endemic. All studies except one used the F1RDT
produced at the Institut Pasteur of Madagascar (F1RDT-IPM), while
the remaining study assessed a F1RDT from New Horizons (F1RDT-
NH), which is utilized by the US CDC. All studies were considered
at high risk of bias for the patient domain, mainly due to the
retrospective design of the studies, the absence of consecutive or
random sampling with clear inclusion and exclusion criteria, or
both. The major findings of this review include the following.
For the diagnosis of any form of plague, the accuracy of F1RDT-IPM
is:
• against culture, sensitivity of 100% (95% CI 82 to 100; 4 studies,
1692 participants; very low-certainty evidence) and specificity
of 70% (95% CI 65 to 75; 4 studies, 2004 participants; very low
certainty evidence) (Summary of findings 1);• against PCR, sensitivity estimates between 72% and 95% and
specificity estimates between 50% and 93%, but meta-analysis
was not possible;• against paired serology, very limited evidence from two
participants in one study.
For the diagnosis of pneumonic plague, the accuracy of F1RDT-IPM
is:
• against culture, sensitivity of 100% (95% CI 0 to 100; 2 studies, 56
participants; very low-certainty evidence) and specificity of 71%
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(95% CI 59 to 80; 2 studies, 297 participants; very low-certainty
evidence) (Summary of findings 2);• against PCR, very limited evidence from four participants in two
studies;• against paired serology, very limited evidence from two
participants in one study.
The performance of F1RDT-IPM for diagnosing bubonic plague:
• against culture, sensitivity of 100% (CI not calculable; 2 studies,
1454 participants; low-certainty evidence), and specificity of
67% (95% CI 65 to 70; 2 studies, 1198 participants; very low-
certainty evidence) (Summary of findings 3);• against PCR, sensitivity of 95% (95% CI 89 to 99; 1 study, 88
participants; very low-certainty evidence), and specificity of 93%
(95% CI 84 to 98; 1 study, 61 participants; very low-certainty
evidence) (Summary of findings 4);• against paired serology, no data.
The performance of the F1RDT-NH for diagnosing any form of
plague against combined culture or paired serology showed
sensitivity of 91% (95% CI 84 to 95) and specificity of 88% (95% CI
83 to 93), as reported by the study authors. When evaluating the
F1RDT-NH with positivity results from 2+, the sensitivity decreased
to 87% (95% CI 80 to 93) and the specificity increased to 98% (95%
CI 93 to 100).
F1RDT for diagnosing pneumonic plague
Early diagnosis of pneumonic plague is critical so that prompt
treatment is started (pneumonic plague is associated with high
fatality rate if leO untreated) and so that preventive measures
are established to limit transmission of the disease (pneumonic
plague can be transmitted from human to human by inhalation of
respiratory droplets produced by coughing).
Against culture results, sensitivity appeared high (100%) but three
participants testing negative in one outbreak in a meta-analysis
that included data for 56 cases resulted in very wide CIs (0 to 100).
The specificity was 71% (95% CI 59 to 80). However, these estimates
came from a small number of participants and there was very low-
certainty evidence.
We used diHerent case scenarios where pretest probability of
plague varied from 0.1% to 4% to 20% to simulate scenarios where
F1RDT could be used in plague endemic areas and in situations
where an outbreak is in progress (Summary of findings 2). This
numerical approach should be interpreted with caution due to the
limitations cited above.
• If F1RDT was used in a hypothetical cohort of 1000 people with
symptoms where one (0.1%) of them actually had pneumonic
plague identified by culture, we estimated that the test would
correctly diagnose the one person with pneumonic plague (1
true positive, 95% CI 0 to 1) and would not miss any people with
pneumonic plague (0 false negatives, 95% CI 0 to 1), but would
diagnose 290 people with pneumonic plague who were culture
negative (290 false positives, 95% CI 200 to 410).• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where 40 (4%) of them actually had pneumonic
plague identified by culture, we estimated that the test would
correctly diagnose all 40 people (40 true positives, 95% CI 0 to
40) and would not miss any people with plague (0 false negative,
95% CI 0 to 40), but would diagnose 278 people with pneumonic
plague who were culture negative (278 false positives, 95% CI
192 to 394). In this case scenario, the PPV would be 12.6%. This
means that among 318 people with positive F1RDT, 12.6% of
them would actually have pneumonic plague (see Figure 10).
The NPV would be 100%, which means that among the 682
people with negative F1RDT, all of them truly will not have
pneumonic plague.• If F1RDT was used in a hypothetical cohort of 1000 people with
symptoms where 200 (20%) of them actually had pneumonic
plague identified by culture, we estimated that the test would
correctly diagnose all 200 people (200 true positives, 95% CI
0 to 200) and would not miss any people with plague (0 false
negative, 95% CI 0 to 200), but would diagnose 232 people
with pneumonic plague who were culture negative (232 false
positives, 95% CI 160 to 328).
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Figure 10.   Flow diagram summarizing the main results in a hypothetical cohort with 4% of people with pneumonic
plague (adapted from van Hoving 2019). F1RDT: F1 antigen rapid diagnostic test.
 
The high sensitivity associated with F1RDT for diagnosing
pneumonic plague means that the test would detect all cases of
pneumonic plague and would not miss any people with diagnosis
of pneumonic plague. The high NPV means that if result of F1RDT
is negative, pneumonic plague can be ruled out. However, the
relatively low specificity and low PPV associated with F1RDT are of
concern for the potential significant repercussions in the context
of this disease. False positives mean that people who do not have
plague will be considered as having plague, with repercussion for
both the person (missing the true diagnosis, unnecessary anxiety
and stigma related to the diagnosis of plague) and for society
(unnecessary social alert and use of economic resources) (Figure
10).
The high apparent level of false positives with culture as the
reference standard may actually be a result of people with plague
testing culture negative; prior antibiotic use, for example, could
cause this. Culture is known to be an imperfect reference standard
for plague, as reminded in Andrianaivoarimanana 2019 where
authors mentioned that "negative culture results might have
resulted from administration of antimicrobial drugs by local health
oHicials before sampling, whereas F1RDT results remained positive
>3 weeks aOer treatment initiation." This would result in an
underestimation of the specificity.
There were insuHicient data to make any estimates against PCR or
paired serology as reference standard.
F1RDT for diagnosing bubonic plague
Early and correct diagnosis of bubonic plague is essential for
correct management of the patient and adequate public health
measures and rodent control.
Two studies assessed F1RDT against culture, with a mean sensitivity
of 100% (95% CI not calculable), and specificity of 67% (95% CI 65
to 70). However, the evidence was low certainty for sensitivity and
very-low certainty for specificity.
One study assessed F1RDT against PCR for three genes (caf1,
pla, Ymt). For caf1, which is considered the most relevant gene
according to experts in the field, sensitivity was 95% (95% CI 89 to
99) and specificity was 93% (95% CI 84 to 98).
We used diHerent case scenarios where pretest probability of
plague varied from 0.1% to 4% to 50% to simulate scenarios where
F1RDT could be used in plague endemic areas and in situations
where an outbreak is in progress. This numerical approach should
be interpreted with caution due to the limitations cited above.
When true cases of bubonic plague were diagnosed with culture,
the main findings were the following (Summary of findings 3).
• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where one (0.1%) of them actually had bubonic
plague identified by culture, we estimated that the test would
correctly diagnose the one person with bubonic plague (1 true
positive, 95% CI not calculable) and would not miss any people
with bubonic plague (0 false negatives, 95% CI not calculable),
but would diagnose 330 people with bubonic plague who were
culture negative (330 false positives, 95% CI 300 to 350).• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where 40 (4%) of them actually had bubonic
plague identified by culture, we estimated that the test would
correctly diagnose all 40 people (40 true positives, 95% CI not
calculable) and would not miss any people with bubonic plague
(0 false negatives, 95% CI not calculable), but would diagnose
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317 people with bubonic plague who were culture negative (317
false positives, 95% CI 288 to 336). In this case scenario, the
(PPV would be 11.2%. This means that among 357 people with
positive F1RDT, 11.2% of them would actually have bubonic
plague. The NPV would be 100%, which means that among the
643 people with negative F1RDT, all of them truly would not have
bubonic plague.• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where 500 (50%) of them actually had bubonic
plague identified by culture, we estimated that the test would
correctly diagnose all 500 people (500 true positives, 95% CI not
calculable) and would not miss any people with bubonic plague
(0 false negative, 95% CI not calculable), but would diagnose
165 people with bubonic plague who were culture negative (165
false positives, 95% CI 150 to 175).
When true cases of bubonic plague are diagnosed with PCR
targeting the caf1 gene, the main findings are the following
(Summary of findings 4).
• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where one (0.1%) of them actually had bubonic
plague identified by PCR, we estimated that the test would
correctly diagnose the one person with bubonic plague (1 true
positive, 95% CI 1 to 1) and would not miss any people with
bubonic plague (0 false negatives, 95% CI 0 to 0), but would
diagnose 70 people with bubonic plague who were PCR negative
(70 false positives, 95% CI 20 to 160).• If F1RDT was used in a hypothetical cohort of 1000 people with
symptoms where 40 (4%) of them actually had bubonic plague
identified by PCR, we estimated that the test would correctly
diagnose 38 people (38 true positives, 95% CI 36 to 40), but
would miss two people with bubonic plague (2 false negatives,
95% CI 0 to 4) and would diagnose 67 people with bubonic
plague who were PCR negative (67 false positives, 95% CI 19
to 154). In this case scenario, the PPV would be 36.1%. This
means that among 105 people with positive F1RDT, 36.1% of
them would actually have bubonic plague. The NPV would be
99.8%, which means that among the 895 people with negative
F1RDT, 99.8% of them truly would not have bubonic plague.• If F1RDT was used in a hypothetical cohort of 1000 people
with symptoms where 500 (50%) of them actually had bubonic
plague identified by PCR, we estimated that the test would
correctly diagnose 475 people (475 true positives, 95% CI 445 to
495), but it would miss 25 people with bubonic plague (25 false
negatives, 95% CI 5 to 55) and would diagnose 35 people with
bubonic plague who were PCR negative (35 false positives, 95%
CI 10 to 80).
Similar to its performance for diagnosing pneumonic plague, the
high sensitivity associated with F1RDT for diagnosing bubonic
plague means that the test would detect all cases (when compared
to culture) or most cases (when compared to PCR) of bubonic
plague. The high NPV means that when F1RDT shows a negative
finding, bubonic plague can be ruled out.
We found higher specificity and PPV estimates when F1RDT was
compared to PCR than to culture. This further demonstrates that
culture is an imperfect reference standard. In the case of prior use
of antibiotics, culture is likely to become negative while PCR might
still be positive by detecting DNA of Y pestis aOer several doses of
antibiotics.
We found no studies that determined the performance of F1RDT
against paired serology for diagnosing bubonic plague.
Strengths and weaknesses of the review
Strengths and weaknesses of the included studies
The small number of studies and participants included in the
analyses is a major limitation of the review with regards to
estimation of accuracy. The sensitivity estimates had broad CIs,
which underlies the imprecision of the estimates. The lower and
higher values of the CIs provide very diHerent scenarios that
would lead to diHerent decisions in practice. The study design
of the included studies contributing to the high risk of selection
bias further weakened our confidence in the results – we judged
all included studies at high risk of bias in the patient selection
domain when applying the QUADAS-2 tool. We found no study
that assessed the accuracy of F1RDT for diagnosing plague by
prospectively recruiting consecutive patients with clear inclusion
and exclusion criteria. There are also some limitations with regards
to the reference standards. Although they were considered at low
risk of introducing bias due to the objective results they provided,
culture could be considered as an imperfect reference standard
when antibiotics are given prior to sample collection, and there is
a lack of standardized targeted gene for identification Y pestis with
PCR.
Strengths and weaknesses of the review process
The findings of this review are based on a comprehensive literature
search with no restriction in language, strict inclusion criteria,
duplicate data extraction, and rigorous assessment of risk of bias
using the QUADAS-2 tool tailored to our review question. The
inclusion of unpublished data at the time of conducting the review
constitutes a strength of the review process.
We attempted to contact study authors when there was poor
reporting that limited data extraction or our judgement on
applicability of the findings.
The prevalence of plague is not well established. For the
hypothetical cohort scenarios, we presented above and in the
'Summary of finding' tables, we chose diHerent values from 0.1% to
50% corresponding to pretest probability in order to contemplate
diHerent scenarios. For this, we considered using RDT where there
was no ongoing outbreak (lower pretest probability) or where there
was ongoing outbreak (higher pretest probability), as well as the
form of plague (signs and symptoms of bubonic plague are more
specific than those of pneumonic plague, therefore the pretest
probability of plague when conducting F1RDT in a person with fever
and a bubo in an endemic area is likely to be higher than when
conducting F1RDT in a person with fever and productive cough).
Sources of heterogeneity could not be explored due to the scarcity
of the included studies and participants. However, we calculated
the test accuracy and presented the findings disaggregated by
form of plague and against diHerent reference standards that are
commonly used in practice.
Applicability of findings to the review question
Inclusion criteria of this review were broad and, as such, were a
good representation of the real scenarios in which F1RDT would be
used. Overall, we had low concern of the applicability of findings
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from the included studies to our review question, when assessed
with the tailored QUADAS-2 tool.
The participant characteristics and settings matched our review
question. For the reference standard domain, all the studies had
low concern for applicability. With regards to the index test domain,
F1RDT was conducted in central laboratories for the majority of
participants who contributed to the primary analyses. In most
cases, it was unclear whether the index test was performed by
specialized and trained staH or by healthcare workers who may not
have been adequately trained or may not have used a rapid test
by immunochromatography previously. Therefore, it is possible
that the accuracy of the test is lower when used on the bedside
of the patients in the field. Another aspect to consider is the
sample collection. Collection of sputum from a sick person during
an outbreak is oOen performed in a context of panic and can be
challenging, leading to collection of saliva instead. In the case of
people with suspected bubonic plague, the obtention of pus from
the bubo is usually simpler but can also be challenging depending
on the size of the bubo. However, this is likely to aHect the yield
of all diagnostic tests performed in the relevant sample (sputum
or bubo aspirate), including F1RDT, culture, and PCR, with no
expected repercussion on the accuracy of the F1RDT against culture
or against PCR. Poor-quality samples (sputum or bubo aspirate)
may lead to a decreased sensitivity when comparing the F1RDT
against paired serology (performed in blood samples).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The use of antigen F1 rapid diagnostic test (F1RDT) needs to be
contextualized in order to assess its implications for practice. Two
main factors may change considerably the interpretation of the
accuracy findings of F1RDT.
The first factor is the form of plague as consequences of false
positives and false negatives might diHer between bubonic and
pneumonic plague, the latter being more severe and transmissible
from human to human. Furthermore, clinical diagnosis of
pneumonic plague can be more diHicult than diagnosis of bubonic
plague, as pneumonic plague shares signs and symptoms of
other, highly prevalent, respiratory infections. This introduces
uncertainty to the assessment of the pretest clinical probability;
the corresponding expected numbers of false positives and false
negatives would also be uncertain. In addition, the diHiculties of
sputum collection and obtaining good-quality sputum samples
leads to limitations of the yield of all the diagnostic techniques
performed on sputum samples. These include F1RDT, but also
culture and polymerase chain reaction. Diagnostic tests performed
in poor-quality samples would not detect some cases of pneumonic
plague. But because this aHects both rapid diagnostic tests and
the reference standards (culture and polymerase chain reaction),
this does not aHect our pooled estimates of F1RDT against these
reference standards.
The second factor is whether the test is used during an outbreak or
not, leading to diHerent prevalence of the disease in which the test
will be used, with subsequent variation in the absolute number of
false positives and false negatives.
When F1RDT is used where plague is known to occur but there
is no declared ongoing outbreak, the test can have a key role in
detecting the beginning of a potential outbreak. In such situations,
it seems clear that F1RDT, which is easy-to-use, cheap, and provides
fast results even in remote or resource-restricted areas would be
desirable. The specificity of the test was estimated to be 70% for
detecting pneumonic plague. The number of false-positive results
is likely to lead to unnecessary social alarm with non-negligible
repercussions. However, F1RDT is being considered as a diagnostic
test that may be used as an add-on to clinical suspicion. Therefore,
clinicians must consider the need of additional testing in case
of positive findings. False-negative results might contribute to
the spread of the disease, and increase risk of mortality for the
missed case. F1RDT showed sensitivity and NPV of 100% to detect
pneumonic plague. A negative result would, therefore, rule out the
disease. The broad confidence interval and the very low-certainty
evidence in the estimate oblige us to consider adding additional
testing in order to rule out plague, and to take into consideration
the clinical suspicion and the real epidemiological scenario.
When F1RDT is used in a context of a declared outbreak, the test
was found to present high NPV and consequently negative results
help to rule out the disease and prompt us to consider alternative
diagnoses. This is significant in panic situations where considerable
numbers of people will present with the fear of having the disease.
However, it is important that the clinician interprets the result
while considering the clinical presentation and epidemiological
context. False negatives might lead to a less negative impact
than in the previous scenario, as the patient is likely to receive
treatment independently of the result of the test (or to be closely
followed) if there is high clinical suspicion of plague. However,
false positives might be more of a concern as the patients will
receive the diagnosis of plague and this is likely to prevent clinicians
considering alternative diagnoses and adequate treatment might
be delayed. False positives are also associated with unnecessary
anxiety and stigma for the patients and their families. With a higher
pretest probability (within a context of an outbreak), cases of false
positives will increase. Therefore, for positive RDTs, the test needs
to be combined with other laboratory evaluations to confirm the
diagnosis, but treatment can be started.
This review contributed to provide accuracy data for the World
Health Organization (WHO) Guideline Development Group Meeting
in September 2019. Both the report of the meeting and the WHO
plague guidelines are expected to be in the public domain later in
2020.
Implications for research
Large, prospective, well-designed studies that recruit people with
suspicion of plague with clear inclusion and exclusion criteria
will help elucidate the true accuracy of F1RDT for the detection
and diagnosis of plague. False-positive rate is likely to have been
overestimated due to the imperfect reference standard for plague.
Research for clarification of the true false-positive rate of F1RDT for
both pneumonic and bubonic plague is required. Clarification of
estimate of pretest probability of plague for diHerent case scenario,
for RDT and other diagnostic methods will also be very valuable
when determining the implication of F1RDT in practice. Research
for new diagnostic techniques that do not require sputum would
help overcome the limitations arising from poor-quality samples.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Retrospective study.
The study authors included the cases of suspected plague that were declared to the national
surveillance system. As such, sampling was not consecutive or random.
Patient characteristics and setting Country: Madagascar.
Plague endemicity: endemic to the central and northern highlands.
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Clinical setting: cases of plague from all over the country.
Study dates: 1998–2016, but cases with RDT compared to reference standard only from 2002
to 2007.
Inclusion criteria: people with suspected plague declared to the national surveillance.
Exclusion criteria: none mentioned.
Target condition: any form of plague.
Sample size: 4221 (from 2002 to 2007), including 411 with unknown RDT findings.
Samples collected: not reported.
Age (median): for all participants included from 1998 to 2016:
Bubonic plague: 11 years (IQR 6 to 20) for suspected case; 13 years (IQR 8 to 24) for confirmed
and presumptive cases.
Pneumonic plague: 26 years (IQR 17 to 40) for suspected case; 29 years (IQR 20 to 42) for con-
firmed and presumptive cases.
Sex ratio (M:F): for all participants included from 1998 to 2016:
Bubonic plague: 1.44 for suspected cases; 1.38 for confirmed and presumptive cases.
Pneumonic plague: 1.08 for suspected cases; 1.28 for confirmed and presumptive cases.
Signs and symptoms presented: not reported.
Antibiotic treatment prior to enrolment: not quantified. Authors stated that, "negative cul-
ture results might have resulted from administration of antimicrobial drugs by local health offi-
cials before sampling, whereas F1RDT results remained positive >3 weeks after treatment initi-
ation."
Index tests Type: RDT produced at the IPM.
Brand name: not specified.
Threshold for positive result: not specified in the paper. However, this is the same RDT de-
scribed in Chanteau 2003a, with a lower detection threshold of 0.5 ng/mL, and used as a posi-
tive/negative test.
Place where the test was performed: not reported.
Transport and storage conditions of the RDT: not reported.
Transport and storage conditions of the samples to be tested: not reported.
Need for sample preparation: not reported.
Who performed the test: not reported.
Blinding of operator to the results of the reference standard: not reported.
Special training provided to personnel performing the test: not reported.
Target condition and reference
standard(s)
Definitions of cases of plague:
Confirmed: Y pestis isolated by culture or mouse inoculation.
Presumptive: no isolation of Y pestis but F1RDT or microscopy positive.
Suspected: no samples available for testing or all test results negative.
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Reference standard(s) used in this review: isolation of Y pestis by culture (and microscopy,
not considered for the purpose of this review).
Place where the reference standard(s) was (were) performed: Central Laboratory for Plague
of the Malagasy Ministry of Health, hosted at the IPM.
Who performed the reference standard(s): not reported.
Blinding of operator to RDT result: not reported. However, there is low risk of introducing
bias in the interpretation of the reference standard (objective finding) by knowing the RDT re-
sult.
Flow and timing Time between collection of sample for RDT and reference standard(s): not reported.
Administration of antibiotics between sample collection for index test and reference stan-
dard: not reported.
Time of sample transportation: not reported.
We judged risk of bias for the RDTs performed between 2002 and 2007.
Comparative  
Notes Source of funding: not reported.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sam-
ple of patients enrolled?
No    
Was a case-control design avoid-
ed?
Yes    
Did the study avoid inappropriate
exclusions?
Unclear    
Did the study considered prior ad-
ministration of antibiotics?
No    
Could the selection of patients
have introduced bias?
  High risk  
Are there concerns that the in-
cluded patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results inter-
preted without knowledge of the
results of the reference standard?
Unclear    
If a threshold was used, was it pre-
specified?
Yes    
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Could the conduct or interpreta-
tion of the index test have intro-
duced bias?
  Unclear risk  
Are there concerns that the in-
dex test, its conduct, or inter-
pretation differ from the review
question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to
correctly classify the target condi-
tion?
Yes    
Were the reference standard re-
sults interpreted without knowl-
edge of the results of the index
tests?
Unclear    
Could the reference standard,
its conduct, or its interpretation
have introduced bias?
  Low risk  
Are there concerns that the tar-
get condition as defined by the
reference standard does not
match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval
between index test and reference
standard?
Unclear    
Did all patients receive the same
reference standard?
Yes    
Were all patients included in the
analysis?
Yes    
Did all patients receive a reference
standard?
Yes    
Could the patient flow have in-
troduced bias?
  Unclear risk  
Andrianaivoarimanana 2019  (Continued)
 
 
Study characteristics
Patient Sampling Retrospective study.
The study authors included all the cases with suspicion of plague during the outbreaks, following the
WHO definition and based on medical records.
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Patient characteristics
and setting
Country: Democratic Republic of the Congo.
Plague endemicity: endemic. The country "has the most active focus of plague worldwide. In the north-
eastern region of Ituri, >1000 suspected cases are reported each year." (quote from manuscript)
Clinical setting: the 2005 outbreak occurred "in a diamond mining camp in a remote area of the Oriental
Province" where "no previous cases of plague had been reported in this region 25 km from the village of
Zobia, Bas-Uele." The 2006 outbreak "occurred in a gold mining camp 200 km from the Zobia camp, near
Bolebole, Haut Uele." (quotes from manuscript)
Study dates: 2 outbreaks reported, from 15 December 2004 to 11 March 2005, and from 21 August to 21
October 2006.
Inclusion criteria: suspected cases of plague following WHO definition based on registries and not follow-
ing reported cases during the outbreaks.
Exclusion criteria: none mentioned.
Target condition: any form of plague, but outbreaks of pneumonic plague. During the first outbreak, 2
cases of septicaemic cases were mentioned.
Sample size: outbreak 2005: 130 cases (5 confirmed, 10 probable, 115 suspected), biological samples col-
lected for 87 cases (173 specimens collected according to Bertherat 2005), RDT performed in 37 cases (35
against culture, 2 against PCR). Outbreak 2006: 162 cases (23 confirmed, 22 probable, 117 suspected), bio-
logical samples collected for 117 cases, RDT performed in 96 cases (against culture).
Samples collected: sputum
Age: not reported.
Sex: not reported.
Signs and symptoms presented: not reported.
Antibiotic treatment prior to enrolment: mentioned but not quantified.
Index tests Type: RDT used included in sampling kits from the IPM. The authors referenced Chanteau 2003a for the
RDT used, produced at the IPM.
Brand name: RDT developed by the Naval Medical Research Institute (Bethesda, MD, USA), as described in
Chanteau 2003a.
Threshold for positive result: not stated in the paper, but 0.5 ng/mL as specified in the referenced study
of Chanteau 2003a, and used as a positive/negative test.
Place where the test was performed: on site for both outbreaks. Repeated at IPM for both outbreaks,
and in Kinsangani during 2005 outbreak.
Transport and storage conditions of the RDT: dipstick contained in an individually vacuum-sealed pack-
age with desiccant to maintain stability and sterility.
Transport and storage conditions of the samples to be tested: for RDT performed on site, no sample
transport required as performed on site immediately during both outbreaks. For culture and other tests,
sputum samples were stored with a swab in Cary Blair medium at 4 °C. During the 2005 outbreak, samples
were first sent to the Kisangani laboratory. The remaining aliquot was stored at 4 °C (serum) and 28 °C to
30 °C (sputum) and sent to Kinshasa and then Madagascar, South Africa, France, and Germany. During the
2006 outbreak, samples were directly sent to the IPM.
Need for sample preparation: sputum (0.5 mL) was diluted and homogenized in 1 mL of phos-
phate-buHered saline using a sterile syringe. 200 μL was then placed in a sterile tube test to apply the dip-
stick.
Who performed the test: a trained biologist from the National Plague Reference Laboratory collected the
sputum sample and performed the RDT.
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Blinding of operator to the results of the reference standard: not reported, but probably yes as test
was performed on site, while reference standard was performed elsewhere.
Special training provided to personnel performing the test: "trained" biologist with no details on the
training received.
Although the test was performed by a trained biologist who also collected the sputum, we judged that
there would probably be low concern of applicability in the field if minimum training was provided to
health workers.
Target condition and
reference standard(s)
Definitions of cases of plague: using WHO definitions but not clearly stated.
Reference standard(s) used in this review:
Culture + standard biochemical tests and phage lysis
RT-PCR (only for the 2005 outbreak)
ELISA for serology from paired samples, collected 10 days apart, a 4-fold increase in antibody titre consid-
ered positive.
(Microscopy and direct fluorescent antibody staining from sputum during the 2005 outbreak were also
used, but not for the purpose of this review.)
Place where the reference standard(s) was (were) performed:
Culture and microscopy: at a temporary second-line regional laboratory in Kisangani, which is 2 hours by
air from the outbreak area, and at IPM for the 2005 outbreak; only at IPM for the 2006 outbreak.
RT-PCR: in Germany for the 2005 outbreak.
ELISA: at Centre de Recherche du Service de Santé des Armées in Grenoble, France.
Who performed the reference standard(s): a biologist from the IPM.
Blinding of operator to RDT result: not reported. However, there is low risk of introducing bias in the in-
terpretation of the reference standard (objective finding) by knowing the RDT result.
Flow and timing Time between collection of sample for RDT and reference standard(s): both RDT and reference stan-
dard (culture and RT-PCR) were conducted from the same biological sample.
Administration of antibiotics between sample collection for index test and reference standard: per-
formed on same samples.
Time of sample transportation: shipments from the affected area to Madagascar took 8–40 days (medi-
an 18.5 days) during the 2005 outbreak, and 4–5 days during the 2006 outbreak.
Comparative  
Notes Source of funding: not reported.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or
random sample of pa-
tients enrolled?
Yes    
Was a case-control de-
sign avoided?
Yes    
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Did the study avoid in-
appropriate exclusions?
Unclear    
Did the study consid-
ered prior administra-
tion of antibiotics?
No    
Could the selection of
patients have intro-
duced bias?
  High risk  
Are there concerns
that the included pa-
tients and setting do
not match the review
question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test re-
sults interpreted with-
out knowledge of the
results of the reference
standard?
Yes    
If a threshold was used,
was it pre-specified?
Yes    
Could the conduct or
interpretation of the
index test have intro-
duced bias?
  Low risk  
Are there concerns
that the index test, its
conduct, or interpre-
tation differ from the
review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference stan-
dards likely to correctly
classify the target con-
dition?
Yes    
Were the reference
standard results inter-
preted without knowl-
edge of the results of
the index tests?
Unclear    
Could the reference
standard, its conduct,
or its interpretation
have introduced bias?
  Low risk  
Are there concerns
that the target condi-
    Low concern
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tion as defined by the
reference standard
does not match the
question?
DOMAIN 4: Flow and Timing
Was there an appropri-
ate interval between in-
dex test and reference
standard?
No    
Did all patients receive
the same reference
standard?
No    
Were all patients in-
cluded in the analysis?
No    
Did all patients receive
a reference standard?
Yes    
Could the patient flow
have introduced bias?
  High risk  
Bertherat 2011  (Continued)
 
 
Study characteristics
Patient Sampling Prospective study as part of the national plague control programme.
The study authors included the cases of suspected plague that were declared to the national surveil-
lance system, but sampling was unclear, and samples included postmortem tissues.
Patient characteristics
and setting
Country: Madagascar.
Plague endemicity: endemic areas.
Clinical setting: central laboratory in the capital Antananarivo; and 26 pilot sites (6 district hospitals and
20 healthcare centres) in remote areas.
Study dates: 1 December 2000 to 30 May 2001 in the capital; 1 December 2000 to 25 January 2001 to test
RDT in remote areas.
Inclusion criteria: people with suspected plague.
Exclusion criteria: none mentioned.
Target condition: any form of plague, although only bubonic and pneumonic plague are mentioned.
Sample size: 671 suspected cases from national surveillance system (central laboratory only) + 128 par-
ticipants from the remote sites (RDT performed both at bedside of the participant and at central labora-
tory).
Samples collected: samples sent to the central laboratory: 691 clinical samples from 671 participants
(bubonic aspirate 643 (93%); sputum 13 (2%); postmortem lung or liver puncture 35 (5%)). Samples from
remote sites: 128 cases with number of samples not specified (bubonic aspirate 123 (96%); sputum: 5
(4%)).
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Although 5% of the samples were postmortem tissues, raising questions about applicability, it was a
small number and, therefore, we judged applicability as low concern.
Age: not reported.
Sex: not reported.
Signs and symptoms presented: not reported.
Antibiotic treatment prior to enrolment: not reported.
Index tests Type: RDT produced at the IPM using a combination of B18–1 and G6–18 antibodies.
Brand name: RDT developed by the Naval Medical Research Institute (Bethesda, MD, USA).
Threshold for positive result: the lower detection threshold of the RDT was 0.5 ng/mL, the test was
used as a positive/negative test.
Place where the test was performed: at the participant's bedside; repeated at the central laboratory.
Transport and storage conditions of the RDT: immunostrips trimmed to a width of 5 mm and stored in
a waterproof bag at 4 °C, or in 5 mL disposable plastic tubes at room temperature at non-central sites.
The RDTs were stored at room temperature during the study (20–30 °C).
Transport and storage conditions of the samples to be tested: samples collected in remote areas
were sent on a swab in Cary Blair agar, at room temperature, to the central laboratory at the IPM.
Need for sample preparation: on arrival at the central laboratory, the specimen was washed out of the
swab by incubation in 1 mL phosphate-buHered saline, and was tested with the 2 reference methods and
with RDT. Sputum samples were diluted with saline or phosphate-buHered saline (1 in 2 to 1 in 10 dilu-
tion).
Who performed the test: at the remote sites, 29 medical doctors, 19 nurses, and 9 health workers.
Blinding of operator to the results of the reference standard: at the remote sites, blinded as RDT per-
formed before sending the sample for reference standard. At central laboratory, blinded as RDT per-
formed before availability of results from reference standard.
Special training provided to personnel performing the test: at the remote sites, onsite training for 3
hours as to how to obtain clinical samples and to use, read, and archive the dipsticks. An illustrated in-
struction guidebook, in French and Malagasy, was given to each centre.
Target condition and ref-
erence standard(s)
Definitions of cases of plague:
Confirmed: culture positive
Presumptive: culture negative but microscopy positive
Negative: culture and microscopy negative
Reference standard(s) used in this review: Gram staining and isolation of Y pestis (either directly from
the participants' samples or after mouse inoculation).
(Immunocapture ELISA for detection of F1 Ag was also used, but not included as reference standard in
this review.)
Place where the reference standard(s) was (were) performed: central laboratory at the IPM.
Who performed the reference standard(s): "Skilled technicians."
Blinding of operator to RDT result: blinded for RDT results from the field, but not blinded for the RDT
results conducted at the central laboratory (communication with the authors). There is low risk of intro-
ducing bias in the interpretation of the reference standard (objective finding) by knowing the RDT result.
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Flow and timing Time between collection of sample for RDT and reference standard(s): the same sample was used for
index test and reference standard for participants from national surveillance; unclear for the remote site
samples.
Administration of antibiotics between sample collection for index test and reference standard: ad-
ministration of antibiotics was not reported; however, at the central laboratory, both RDT and reference
standards were performed from the same sample.
Time of sample transportation: the median transport time to the central laboratory of the 691 samples
was 8 days, ranging from 0 to 66 days (25th percentile 5 days, 75th percentile 14 days). However, there
was no significant difference in the mean transport time between bacteriologically confirmed and nega-
tive specimens.
Comparative  
Notes Source of funding: Institut Pasteur, Paris (Grant PTR 2000–11), IPM, and the Ministry of Health of Mada-
gascar (World Bank IDA 3302 MAG).
Sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of re-
port.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or ran-
dom sample of patients
enrolled?
No    
Was a case-control de-
sign avoided?
Yes    
Did the study avoid inap-
propriate exclusions?
Unclear    
Did the study considered
prior administration of
antibiotics?
No    
Could the selection of
patients have intro-
duced bias?
  High risk  
Are there concerns
that the included pa-
tients and setting do
not match the review
question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Yes    
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If a threshold was used,
was it pre-specified?
Yes    
Could the conduct or
interpretation of the
index test have intro-
duced bias?
  Low risk  
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference stan-
dards likely to correctly
classify the target condi-
tion?
Yes    
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
tests?
No    
Could the reference
standard, its conduct,
or its interpretation
have introduced bias?
  Low risk  
Are there concerns that
the target condition as
defined by the refer-
ence standard does not
match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate
interval between index
test and reference stan-
dard?
No    
Did all patients receive
the same reference stan-
dard?
Yes    
Were all patients includ-
ed in the analysis?
Yes    
Did all patients receive a
reference standard?
Yes    
Could the patient flow
have introduced bias?
  High risk  
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Study characteristics
Patient Sampling Prospective study.
Sampling not described.
Patient characteristics and setting Country: Madagascar and Uganda.
Plague endemicity: endemic areas.
Clinical setting: 35 clinics in Madagascar and 12 clinics in Uganda.
Study dates: 2004–2006 in Madagascar, 2004–2017 in Uganda.
Inclusion criteria: not reported.
Exclusion criteria: none mentioned.
Target condition: any form of plague.
Sample size: ≥ 254.
Samples collected: bubo aspirates and sputum.
Age: not reported.
Sex: not reported.
Signs and symptoms presented: not reported.
Antibiotic treatment prior to enrolment: not reported.
Index tests Type: RDT produced by New Horizons.
Brand name: not reported.
Threshold for positive result: lower detection threshold of RDT was 1 ng/mL (personal
communication), the test was used as semi-quantitative test (from 1+ to 4+) and considered
positive for analysis from 1+ and from 2+. Those are the findings presented and we do not
know if this was prespecified in the protocol and methods of the study.
Place where the test was performed: central laboratory.
Transport and storage conditions of the RDT: not reported.
Transport and storage conditions of the samples to be tested: not reported.
Need for sample preparation: not reported.
Who performed the test: not reported.
Blinding of operator to the results of the reference standard: not reported.
Special training provided to personnel performing the test: not reported.
Target condition and reference stan-
dard(s)
Definitions of cases of plague:
Confirmed case: 1 of the following criteria: isolate from a clinical source identified as Y pestis
(colony morphology and 2/4 tests positive: bacteriophage lysis, F1 detection, PCR, Y pestis
biochemical profile); with/without 4-fold difference in F1 antibody titre between paired
serum samples; with/without F1 Ag detection (bubo, sputum, blood) by immunochromatog-
raphy in endemic focus when no other confirmatory tests can be performed.
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Presumptive case: detection by 2 target RT-PCR.
Suspect case: rapid onset of fever of at least 38 °C, and 1 of the following: ≥ 1 buboes, de-
fined as a tender lymph node swelling > 1 cm in diameter, or clinical suspicion of pneumonic
plague (e.g. prostration, cough, increased respiratory rate, haemoptysis, purulent sputum,
or a combination of these), or clinical suspicion of plague and epidemiological link to other
cases.
Reference standard(s) used in this review:
Culture
Serological analysis with a 4-fold increase in titre in the second serum sample.
Place where the reference standard(s) was (were) performed: culture at the central labo-
ratory, paired serology at the US CDC.
Who performed the reference standard(s): not reported.
Blinding of operator to RDT result: not reported. However, there is low risk of introducing
bias in the interpretation of the reference standard (objective finding) by knowing the RDT
result.
Flow and timing Time between collection of sample for RDT and reference standard(s): collected on
same day.
Administration of antibiotics between sample collection for index test and reference
standard: unlikely although not reported.
Time of sample transportation: not reported.
Comparative  
Notes Source of funding: not reported.
Collaborators: the CDC, Ministry of Health and IPM and Ministry of Health and Uganda Virus
Research Institute from Uganda.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample
of patients enrolled?
Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate ex-
clusions?
Unclear    
Did the study considered prior ad-
ministration of antibiotics?
Unclear    
Could the selection of patients
have introduced bias?
  Unclear risk  
Are there concerns that the in-
cluded patients and setting do not
match the review question?
    Unclear
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DOMAIN 2: Index Test (All tests)
Were the index test results interpret-
ed without knowledge of the results
of the reference standard?
Unclear    
If a threshold was used, was it pre-
specified?
Unclear    
Could the conduct or interpretation
of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index
test, its conduct, or interpretation
differ from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to
correctly classify the target condi-
tion?
Yes    
Were the reference standard results
interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its
conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target
condition as defined by the refer-
ence standard does not match the
question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval be-
tween index test and reference stan-
dard?
Unclear    
Did all patients receive the same ref-
erence standard?
Unclear    
Were all patients included in the
analysis?
Unclear    
Did all patients receive a reference
standard?
Unclear    
Could the patient flow have intro-
duced bias?
  Unclear risk  
Petersen 2018  (Continued)
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Study characteristics
Patient Sampling Retrospective study.
The study authors included cases with suspicion of plague who were declared to the national surveil-
lance system. As such, sampling was not consecutive or random.
Patient characteristics and
setting
Country: Madagascar.
Plague endemicity: endemic.
Clinical setting: surveillance data.
Study dates: 3 study periods:
Period 1: 2002–2007 for all clinical forms (same period as in Andrianaivoarimanana 2019, but exclud-
ing those with transport > 7 days and those who received antibiotics prior to sample collection).
Period 2: 11 September to 3 October 2017 for all pulmonary plague cases from non-endemic zones.
Period 3: 2018 to 3 April 2019 for all clinical forms.
Inclusion criteria: all clinically suspected cases reported to the national surveillance system with RDT
performed at the Central Laboratory for Plague, when RDT and culture were performed independent-
ly and systematically (periods when RDTs were used as a screening test for bacteriology testing were
not considered).
Exclusion criteria: cases for which time of transport > 7 days, and cases who have declared to have
taken antibiotics prior to sample collection.
Target condition: all forms of plague
Sample size: after exclusion and after removing missing cases:
Period 1: 2468 (2319 bubonic + 149 pulmonic cases)
Period 2: 100 (33 + 67)
Period 3: 192 (151 + 41)
Samples collected: bubo aspirate, sputum, postmortem organ puncture.
Age: not reported.
Sex: not reported.
Signs and symptoms presented: not reported.
Antibiotic treatment prior to enrolment: none; this was an exclusion criteria.
Index tests Type: RDT produced at the IPM.
Brand name: not specified.
Threshold for positive result: not specified in manuscript. However, this is the same RDT described
in Chanteau 2003a, and therefore the threshold is 0.5 ng/mL, and used as a positive/negative test.
Place where the test was performed: Central Laboratory for Plague at the IPM.
Transport and storage conditions of the RDT: transport not required as RDT conducted where there
are produced. Storage conditions not reported.
Transport and storage conditions of the samples to be tested: not reported.
Need for sample preparation: not reported.
Rajerison 2020 
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Who performed the test: not clearly reported, but by trained staH at the central laboratory as study
authors mentioned "RDT performed at Central Laboratory for Plague to avoid bias due to handling ef-
fect in Health Care Centred despite training."
Blinding of operator to the results of the reference standard: not reported.
Special training provided to personnel performing the test: not reported.
Target condition and refer-
ence standard(s)
Definitions of cases of plague:
Confirmed: clinically suspected cases with positive RDT and positive molecular biology, or positive
culture.
Probable: clinically suspected cases with positive RDT or positive molecular biology and culture nega-
tive or not performed.
Suspected: all clinically suspected plague cases that meet the clinical and epidemiological crite-
ria as per WHO recommendations (compatible clinical presentation (fever, sepsis syndrome, lym-
phadenopathy, acute pneumonitis, or a combination of these) and epidemiological features (such as
exposure to infected animals or humans, evidence of flea bites, residence in or travel to a known en-
demic focus within the previous 10 days, or a combination of these)).
Reference standard(s) used in this review: 'bacteriology,' this is isolation of Y pestis by culture and
or mouse inoculation (communication with authors).
Place where the reference standard(s) was (were) performed: Central Laboratory for Plague at the
IPM.
Who performed the reference standard(s): not reported.
Blinding of operator to RDT result: not reported. However, there is low risk of introducing bias in the
interpretation of the reference standard (objective finding) by knowing the RDT result.
Flow and timing Time between collection of sample for RDT and reference standard(s): not reported.
Administration of antibiotics between sample collection for index test and reference standard:
none, as per exclusion criteria.
Time of sample transportation: ≤ 7 days, as per exclusion criteria.
Comparative  
Notes Source of funding: financial support from the Wellcome Trust/Department for International Develop-
ment (contract no 211309/Z/18/Z) to perform the analyses.
Support USAID (Grant no AID-687-G-13-0003) for the implementation of the RT-PCR technique, se-
cured transportation of the biological samples as well as financing for the additional human re-
sources needed by the Central Laboratory for Plague and the Epidemiology Units at IPM. WHO provid-
ed funding for the acquisition of new equipment to accelerate RDT production during the 2017 epi-
demic.
The funding source had no role in study design or collection, analysis, and interpretation of data.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or ran-
dom sample of patients en-
rolled?
No    
Rajerison 2020  (Continued)
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Was a case-control design
avoided?
Yes    
Did the study avoid inap-
propriate exclusions?
Unclear    
Did the study considered
prior administration of an-
tibiotics?
Yes    
Could the selection of pa-
tients have introduced
bias?
  High risk  
Are there concerns that
the included patients and
setting do not match the
review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results
interpreted without knowl-
edge of the results of the
reference standard?
Unclear    
If a threshold was used, was
it pre-specified?
Yes    
Could the conduct or in-
terpretation of the index
test have introduced bias?
  Unclear risk  
Are there concerns that
the index test, its conduct,
or interpretation differ
from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards
likely to correctly classify
the target condition?
Yes    
Were the reference stan-
dard results interpreted
without knowledge of the
results of the index tests?
Unclear    
Could the reference stan-
dard, its conduct, or its in-
terpretation have intro-
duced bias?
  Low risk  
Are there concerns that
the target condition as
defined by the reference
    Low concern
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standard does not match
the question?
DOMAIN 4: Flow and Timing
Was there an appropriate
interval between index test
and reference standard?
Yes    
Did all patients receive the
same reference standard?
Yes    
Were all patients included
in the analysis?
Yes    
Did all patients receive a
reference standard?
Yes    
Could the patient flow
have introduced bias?
  Low risk  
Rajerison 2020  (Continued)
 
 
Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
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Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2002-2007 Bubonic)  (Continued)
 
 
Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
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Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Rajerison 2020 (2002-2007 Pneumonic)  (Continued)
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Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2002-2007 Pneumonic)  (Continued)
 
 
Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
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Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2017-2018 Bubonic)  (Continued)
 
 
Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard?      
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2017-2018 Pneumonic)  (Continued)
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Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
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Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2018-2019 Bubonic)  (Continued)
 
 
Study characteristics
Patient Sampling See Rajerison 2020.
Patient characteristics and setting See Rajerison 2020.
Index tests See Rajerison 2020.
Target condition and reference standard(s) See Rajerison 2020.
Flow and timing See Rajerison 2020.
Comparative  
Notes See Rajerison 2020.
Methodological quality
Item Authors'
judgement
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? Unclear    
Did the study considered prior administration of antibiotics? Unclear    
Could the selection of patients have introduced bias?   Unclear risk  
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Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Unclear    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Unclear risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Unclear    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? Unclear    
Did all patients receive a reference standard? Unclear    
Could the patient flow have introduced bias?   Unclear risk  
Rajerison 2020 (2018-2019 Pneumonic)  (Continued)
 
 
Study characteristics
Patient Sampling Retrospective study.
Study authors included all cases with suspicion of plague during outbreaks. Consequently, there
was no consecutive or random sampling. Furthermore, RDT was only performed in 2 participants,
as biological samples could not be retrieved for the first cases when plague was not suspect-
ed yet, and other cases were suspected on recovery, with no biological samples taken in acute
phase.
Patient characteristics and set-
ting
Country: Madagascar.
Richard 2015 
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Plague endemicity: endemic in Madagascar, although the remote region where the outbreak oc-
curred was supposedly free of Y pestis.
Clinical setting: 7 villages along a field path in the communes of Ambarakaraka and Anaborano,
Ambilobe District, in the north of Madagascar.
Study dates: outbreak in January 2011.
Inclusion criteria: all participants with suspected plague during this outbreak.
Exclusion criteria: none mentioned.
Target condition: any form of plague, but outbreak of pneumonic plague.
Sample size: 20 cases in the outbreak, but RDT was only performed on 2 participants.
Samples collected: sputum.
Age: not reported.
Sex: not reported.
Signs and symptoms presented: sudden onset of fever, cough, haemoptysis, and chest pain.
Antibiotic treatment prior to enrolment: both participants received antibiotics, but unclear
whether before or after biological sample collection.
We judged there were unclear concerns regarding applicability, as the test was performed on only
2 people, with limited information.
Index tests Type: the authors referenced Chanteau 2003a for the RDT used, produced at the IPM.
Brand name: RDT developed by the Naval Medical Research Institute (Bethesda, MD, USA), as de-
scribed in Chanteau 2003a.
Threshold for positive result: not stated in the paper, but Ag threshold of 0.5 ng/mL as specified
in the referenced study Chanteau 2003a, and used as a positive/negative test.
Place where the test was performed: unclear, probably bedside of the participant.
Transport and storage conditions of the RDT: not reported.
Transport and storage conditions of the samples to be tested: not reported.
Need for sample preparation: not reported.
Who performed the test: not reported.
Blinding of operator to the results of the reference standard: not reported. It is likely that RDT
was performed at the bedside of the participants, and, therefore, interpreted before sending sam-
ple for reference standard.
Special training provided to personnel performing the test: not reported.
Target condition and reference
standard(s)
Definitions of cases of plague:
Confirmed: 4-fold increase in titre of antibodies against F1 Ag in paired serum samples or a posi-
tive culture.
Presumptive: positive serological result for antibodies anti F1 Ag.
Suspected: specific clinical symptoms.
Reference standard(s) used in this review:
Culture + inoculation in mice.
Richard 2015  (Continued)
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Serological analysis with a 4-fold increase in titre in the second serum sample.
Molecular analysis: PCR (specific for the Y. pestis plasminogen activator and capsule Ag fraction 1
genes).
Place where the reference standard(s) was (were) performed: WHO Collaborating Center for
Plague at the IPM in Antananarivo.
Who performed the reference standard(s): not reported.
Blinding of operator to RDT result: not reported. However, there is low risk of introducing bias in
the interpretation of the reference standard (objective finding) by knowing the RDT result.
Flow and timing Time between collection of sample for RDT and reference standard(s): not reported.
Administration of antibiotics between sample collection for index test and reference stan-
dard: not reported.
Time of sample transportation: distance > 900 km, time of transportation not reported.
The judgements we make below are considering only the 2 participants for whom RDT was per-
formed.
Comparative  
Notes Source of funding: supported by the IPM, the President's Malaria Initiative/US Agency for In-
ternational Development, and the US Department of Homeland Security (project no. DHS-09-
ST-108-001/MGN3EL7-01).
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No    
Was a case-control design
avoided?
Yes    
Did the study avoid inappropri-
ate exclusions?
Unclear    
Did the study considered prior
administration of antibiotics?
No    
Could the selection of patients
have introduced bias?
  High risk  
Are there concerns that the in-
cluded patients and setting
do not match the review ques-
tion?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results in-
terpreted without knowledge
Unclear    
Richard 2015  (Continued)
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of the results of the reference
standard?
If a threshold was used, was it
pre-specified?
Yes    
Could the conduct or interpre-
tation of the index test have
introduced bias?
  Unclear risk  
Are there concerns that the in-
dex test, its conduct, or inter-
pretation differ from the re-
view question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards like-
ly to correctly classify the target
condition?
Yes    
Were the reference standard re-
sults interpreted without knowl-
edge of the results of the index
tests?
Unclear    
Could the reference standard,
its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the
target condition as defined by
the reference standard does
not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear    
Did all patients receive the
same reference standard?
Yes    
Were all patients included in the
analysis?
Yes    
Did all patients receive a refer-
ence standard?
Yes    
Could the patient flow have
introduced bias?
  Unclear risk  
Richard 2015  (Continued)
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Patient Sampling Retrospective study.
Study authors included all cases with symptoms consistent with the clinical diagnosis
of bubonic plague during the study period. Consequently, there was no consecutive or
random sampling.
Patient characteristics and setting Country: Madagascar.
Plague endemicity: endemic.
Clinical setting: endemic plague areas in Madagascar.
Study dates: February 2007 to December 2008.
Inclusion criteria: suspicion of bubonic plague.
Exclusion criteria: none mentioned.
Target condition: bubonic plague.
Sample size: 149.
Samples collected: bubo aspirates.
Age: range 1–72 years; mean 17 years.
Sex: 59 (39.6%) females.
Signs and symptoms presented: fever and lymphadenopathy.
Antibiotic treatment prior to enrolment: not reported.
Index tests Type: F1RDT produced at the IPM, not clearly mentioned by study authors but in refer-
ences.
Brand name: not reported.
Threshold for positive result: not reported. Test was regarded positive if ≥ 1 of tests
conducted either onsite or at the IPM was positive.
Place where the test was performed: onsite instantly, and repeated at the IPM.
Transport and storage conditions of the RDT: not reported.
Transport and storage conditions of the samples to be tested: not required as sam-
ple tested instantly onsite.
Need for sample preparation: obtention of bubo aspirate after injection of 1 mL ster-
ile saline solution before treatment.
Who performed the test: not reported.
Blinding of operator to the results of the reference standard: not reported.
Special training provided to personnel performing the test: not reported.
Target condition and reference standard(s) Definitions of cases of plague:
Confirmed: culture positive.
Presumptive: F1-Ag immunochromatography positive or specific PCR assay positive, or
both.
Suspicion: clinical diagnosis.
Riehm 2011  (Continued)
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Reference standard(s) used in this review:
Culture.
RT-PCR.
Place where the reference standard(s) was (were) performed: IPM in Antananarivo.
Who performed the reference standard(s): not reported.
Blinding of operator to RDT result: not reported. However, there is low risk of intro-
ducing bias in the interpretation of the reference standard (objective finding) by know-
ing the RDT result.
Flow and timing Time between collection of sample for RDT and reference standard(s): not report-
ed.
Administration of antibiotics between sample collection for index test and refer-
ence standard: not reported.
Time of sample transportation: due to unfavourable economic circumstances, the
transport of samples to the central reference laboratory for human plague, Institut
Pasteur Antananarivo, Madagascar, took several days or even weeks at ambient air
temperature (5 °C to 30 °C).
Comparative  
Notes Source of funding: not reported.
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of
patients enrolled?
No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclu-
sions?
Unclear    
Did the study considered prior administra-
tion of antibiotics?
Unclear    
Could the selection of patients have in-
troduced bias?
  High risk  
Are there concerns that the included pa-
tients and setting do not match the re-
view question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted
without knowledge of the results of the ref-
erence standard?
Unclear    
Riehm 2011  (Continued)
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If a threshold was used, was it pre-speci-
fied?
Unclear    
Could the conduct or interpretation of
the index test have introduced bias?
  Unclear risk  
Are there concerns that the index test,
its conduct, or interpretation differ from
the review question?
    Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correct-
ly classify the target condition?
Yes    
Were the reference standard results inter-
preted without knowledge of the results of
the index tests?
Unclear    
Could the reference standard, its con-
duct, or its interpretation have intro-
duced bias?
  Low risk  
Are there concerns that the target con-
dition as defined by the reference stan-
dard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between
index test and reference standard?
No    
Did all patients receive the same reference
standard?
Yes    
Were all patients included in the analysis? Yes    
Did all patients receive a reference stan-
dard?
Yes    
Could the patient flow have introduced
bias?
  High risk  
Riehm 2011  (Continued)
Ag: antigen; CDC: Centers for Disease Control and Prevention; ELISA: enzyme-linked immunosorbent assay; F: female; IQR: interquartile
range; IPM: Institut Pasteur of Madagascar; M: male; PCR: polymerase chain reaction; RDT: rapid diagnostic test; RT-PCR: real-time
polymerase chain reaction; USAID: United States Agency for International Development; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abedi 2018 Although this study fulfilled the inclusion criteria, it described 5 outbreaks including the 2 out-
breaks described in Bertherat 2011, without adding any data. For the other 3 outbreaks, there are
insufficient data to draw 2×2 tables.
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Study Reason for exclusion
Anish 2013 Ineligible index test (array).
Asaku 2014 Ineligible index test. Conference abstract that potentially met inclusion criteria. Contacted author
to request full-text publications. 2 publications were sent with no data regarding plague RDT.
Bertherat 2007 Outbreak of bubonic plague in Algeria. Insufficient data to draw 2×2 tables.
Bosch unpublished Ineligible study design (statistical modelling to estimate the performance of diagnostic tests for
plague).
Cabanel 2013 Described a plague outbreak in Libya. Insufficient data to draw 2×2 tables.
Chanteau 2000a Outdated RDT from Institut Pasteur of Madagascar.
Chanteau 2000b Ineligible index test (rapid test based on ELISA).
Chanteau 2003b Ineligible study design (narrative review).
Chanteau 2005 Ineligible study design (narrative review).
Choi 2017 Experimental setting (in vitro).
da Silva 2012 Experimental setting (in vitro).
Dennis 2003 Ineligible study design (commentary).
Goel 2015 Ineligible study design (narrative review).
Hai 2007 Ineligible study design (commentary).
Migliani 2006 Ineligible index test (no use of RDT during the reported outbreak).
MMWR 2009 Ineligible index test (no use of RDT during the reported outbreak).
Ramasindrazana 2017 Ineligible index test (no RDT was used in humans only in mice).
Randremanana 2019 People from an outbreak already included in Rajerison 2020, with no data that we could extract on
RDT findings to draw a 2×2 table.
Ratsitorahina 2000 Outdated RDT from Institut Pasteur of Madagascar.
Simon 2013 Experimental setting (in vitro).
Splettstoesser 2004 Ineligible index test (rapid test based on ELISA).
Tomaso 2007 Experimental setting (in vitro).
Tsui 2015 Experimental setting (simulated samples of Y pestis within human serum).
UCLA 2003 Ineligible study design (commentary).
Wang 2005 Experimental setting (in vitro).
Xu 2008 Ineligible participants (animals).
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Study Reason for exclusion
Yan 2006 Ineligible participants (animals).
Yang 2006 Experimental setting, using animal samples and human samples (including postmortem tissues) to
assess the efficacy of several diagnostic tests for plague.
Yao 2013 Ineligible index test (immunochromatography test based on the detection of F1 antibodies).
Zasada 2015 Experimental setting (in vitro).
Zasada 2018 Experimental setting (in vitro).
Zhang 2014 Experimental setting (in vitro).
Zhu 2006 Experimental setting (in vitro).
ELISA: enzyme-linked immunosorbent assay; RDT: rapid diagnostic test.
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 F1RDT versus culture for all forms of plague, primary analysis 9 3696
2 F1RDT versus culture for all forms of plague, sensitivity analysis 1 8 5038
3 F1RDT versus culture for all forms of plague, sensitivity analysis 2 8 3629
 
 
Test 1.   F1RDT versus culture for all forms of plague, primary analysis
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Test 2.   F1RDT versus culture for all forms of plague, sensitivity analysis 1
 
 
Test 3.   F1RDT versus culture for all forms of plague, sensitivity analysis 2
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Study ID Setting, date n Form of
plague
Samples for RDT RDT manufacturer Location of
performance
of RDT
Reference
standards
Andrianaivoa-
rimanana
2019
Madagascar
Surveillance 2002–
2007a
4221 (3810 analyzed, 411
unknown)
BPb
PPb
Not reported Institut Pasteur Mada-
gascar
Not reported Culture
Bertherat
2011
DRC
2 outbreaks: 2005 and
2006
2005 outbreak: 130, RDT
performed in 37
2006 outbreak: 162, RDT
performed in 96
PP Sputum Institut Pasteur Mada-
gascar
Unclearc Culture
PCR
Chanteau
2003a
Madagascar
2000–2001
671, RDT performed in
691 samples
BP (642)
PP (20)
Unknown (9)
Bubo aspirate
Sputum
Postmortem organ
puncture
Institut Pasteur Mada-
gascar
Central labora-
toryd
Culture
Petersen 2018 Madagascar 2004–
2006
Uganda 2004–2017
≥ 254 At least:
BP (225)
PP (26)
SP (2)
Cutaneous (2)
Bubo aspirate
Sputum
New Horizons Central labora-
tory
Culture
Paired serolo-
gy
Rajerison
2020
Madagascar
3 periods:
(a) 2002–2007
(b) 2017–2018
(c) 2018–2019
(A) 2468
(B) 100
(C) 192
BP (2503)
PP (257)
Bubo aspirate
Sputum
Postmortem organ
puncture
Institut Pasteur Mada-
gascar
Central labora-
tory
Culture
Richard 2015 Madagascar
Outbreak 2011
20, RDT performed in 2 PP Sputum Institut Pasteur Mada-
gascar
Not reported Culture
PCR
Paired serolo-
gy
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Riehm 2011 Madagascar
2007–2008
149 BP Bubo aspirate Institut Pasteur Mada-
gascar
Bedside and
central labora-
tory
Culture
PCR
Table 1.   Summary of included studies  (Continued)
Abbreviations: BP: bubonic plague; n: number; PP: pneumonic plague; PCR: polymerase chain reaction; RDT: rapid diagnostic test; SP: septicaemic plague.
aAdditional data are reported for 1998 to 2001 and 2008 to 2018. However, for these two periods, there were no data available in order to assess diagnostic test accuracy of the RDT.
bNo disaggregated data between BP and PP.
cRDTs were performed onsite and repeated at a central laboratory. However, it was unclear which findings authors used for analysis.
dRDTs were performed at the participant's bedside and repeated at the central laboratory. However, authors used the findings from the test performed at the central laboratory
for analysis.
eThe authors determined positive disease status when either RDT performed onsite or at the central laboratory was positive. Five cases had a positive RDT when performed onsite
but negative when repeated at the central laboratory; and two cases had a negative RDT when performed onsite but positive when repeated at the central laboratory.
 
 
Study ID F1RDT Form of plague TP FP FN TN Sensitivity (95% CI) Specificity (95% CI)
F1RDT versus culture
Andrianaivoarimanana
2019
IPM Bubonic and
pneumonic
(NDD)
1420 979 0 1411 100% (100 to 100) 59% (57 to 61)
Bertherat 2011 (2005
outbreak)
IPM Pneumonic 0 17 0 18 Not estimable 51% (34 to 69)
Bertherat 2011 (2006
outbreak)
IPM Pneumonic 4 19 0 73 100% (40 to 100) 79% (70 to 87)
Chanteau 2003a IPM Bubonic and
pneumonic
(NDD)
151 128 31 381 83% (77 to 88) 75% (71 to 79)
Pneumonic 40 45 0 64 100% (91 to 100) 59% (49 to 68)Rajerison 2020 (2002–
2007)
IPM
Bubonic 1328 324 0 667 100% (100 to 100) 67% (64 to 70)
Pneumonic 1 23 3 40 25% (1 to 81) 63% (50 to 75)Rajerison 2020 (2017–
2018)
IPM
Bubonic 22 2 0 9 100% (85 to 100) 82% (48 to 98)
Table 2.   Disaggregated findings of F1RDT for diagnosing plague 
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Pneumonic 8 6 0 27 100% (63 to 100) 82% (65 to 93)Rajerison 2020 (2018–
2019)
IPM
Bubonic 57 23 0 71 100% (94 to 100) 76% (66 to 84)
Richard 2015 IPM Pneumonic 0 2 0 0 Not estimable Not estimable
Riehm 2011 a IPM Bubonic 47 41 0 61 100% (92 to 100) 60% (50 to 69)
F1RDT versus PCR
Bertherat 2011 (2005
outbreak)b
IPM Pneumonic 0 1 0 1 Not estimable 50% (1 to 99)
Richard 2015 (pla and
caf1)
IPM Pneumonic 2 0 0 0 Not estimable Not estimable
Riehm 2011 (caf1)c IPM Bubonic 84 4 4 57 95% (89 to 99) 93% (84 to 98)
Riehm 2011 (pla)c IPM Bubonic 86 2 34 27 72% (63 to 80) 93% (77 to 99)
Riehm 2011 (Ymt)c IPM Bubonic 80 8 7 54 92% (84 to 97) 87% (76 to 94)
F1RDT versus paired serology
Richard 2015 IPM Pneumonic 2 0 0 0 100% (16 to 100) Not estimable
F1RDT versus culture or paired serology
Petersen 2018 NH Bubonic, pneu-
monic, septi-
caemic, cuta-
neous
NRd NRd NRd NRd 91% (84 to 95)d 88% (83 to 93)d
Table 2.   Disaggregated findings of F1RDT for diagnosing plague  (Continued)
Abbreviations: CI: confidence interval; F1RDT: F1 antigen rapid diagnostic test; FN: false negative; FP: false positive; IPM: Institut Pasteur of Madagascar; NDD: no disaggregated
data; NH: New Horizons; NR: not reported; PCR: polymerase chain reaction; TN: true negative; TP: true positive.
Note: we presented findings for positivity of F1RDT interpreted from 1+.
aThe authors determined positive disease status when either RDT performed onsite or at the central laboratory was positive. Five cases had a positive RDT when performed onsite
but negative when repeated at the central laboratory; and two cases had a negative RDT when performed onsite but positive when repeated at the central laboratory.
bThere were no participants with both PCR and F1RDT findings reported from the 2006 outbreak. The gene tested by PCR during the 2005 outbreak was not specified.
cThree genes (caf1, pla, Ymt) were tested for the same group of participants. Therefore, findings for these three rows corresponded to the same cohort of participants.
dThere was limited published available data for this study. Raw data on TP, TN, FP, and FN were not reported. The sensitivity and specificity estimates are those reported by the
study authors.
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 (plague):ti,ab,kw
#2 yersinia pestis
#3 #1 or #2
#4 diagnosis or diagnostic* or detect*
#5 RDT*
#6 "Enzyme-Linked Immunosorbent Assay" or ELISA
#7 lateral flow
#8 chromatograph*
#9 immunochromatograph*
#10 #4 or #5 or #6 or #7 or #8 or #9
#11 #3 and #10
MEDLINE (PubMed)
 
Search Query
#1 Search plague Field: Title/Abstract
#2 Search yersinia pestis Field: Title/Abstract
#3 Search "y pestis" Field: Title/Abstract
#4 Search "Plague"[Mesh]
#5 Search "Yersinia pestis"[Mesh]
#6 Search (((#5) OR #4 OR #3) OR #2 OR #1
#7 Search diagnosis or diagnostic* or detect* Field: Title/Abstract
#8 Search RDT* Field: Title/Abstract
#9 Search "rapid diagnos* " Field: Title/Abstract
#10 Search "Enzyme-Linked Immunosorbent Assay" or ELISA Field: Title/Abstract
#11 Search "lateral flow" Field: Title/Abstract
#12 Search chromatograph* Field: Title/Abstract
#13 Search immunochromatograph* Field: Title/Abstract
#14 Search dipstick* Field: Title/Abstract
#15 Search F1 antigen* Field: Title/Abstract
#16 Search F1RDT* Field: Title/Abstract
#17 Search "rapid identification" Field: Title/Abstract
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#18 Search ((test kit [Title/Abstract] OR test kits [Title/Abstract] OR testing kit [Title/Abstract] OR test-
ing kits [Title/Abstract]))
#19 Search "Immunoassay"[Mesh]
#20 Search "Reagent Kits, Diagnostic"[Mesh]
#21 Search "Reagent Strips"[Mesh]
#22 Search "Sensitivity and Specificity"[Mesh]
#23 Search (((((((((((((#22) OR #21) OR #20) OR #19) OR #18) OR #17) OR #16) OR #15) OR #14) OR #13) OR
#12) OR #11 OR #10) OR #9 OR #8 OR #7
#24 Search #23) AND #6
  (Continued)
 
Embase (Ovid)
1 plague.mp. or *plague/
2 yersinia pestis.mp. or Yersinia pestis/
3 *diagnosis/
4 diagnostic test/
5 RDT*.mp.
6 "rapid diagnos$ test$ ".ab. or "rapid diagnos$ test$".ti.
7 ELISA.mp. or enzyme linked immunosorbent assay/
8 immunochromatography/ or immunoaHinity chromatography/ or chromatography/ or immunochromatograph*.mp.
9 lateral flow.mp.
10 1 or 2
11 3 or 4 or 5 or 6 or 7 or 8 or 9
12 10 and 11
Science Citation Index-Expanded (Web of Science)
# 3#2 AND #1
Indexes=SCI-EXPANDED, CPCI-S, Timespan=All years
# 2TS=(RDT* or "Enzyme-Linked Immunosorbent Assay" or ELISA) OR TS=("lateral flow" or chromatography or immunochromatography)
Indexes=SCI-EXPANDED, CPCI-S, Timespan=All years
# 1TOPIC: (plague or yersinia pestis)
Indexes=SCI-EXPANDED, CPCI-S, Timespan=All years
Google Scholar = plague and diagnosis, plague and RDT
Clinicaltrials.gov, WHO ICTRP: plague and diagnosis, plague and RDT
Appendix 2. Data extraction form
 
Study ID First author
Year of publication
Journal of publication
Setting Country
Plague prevalence and endemicity in study setting
Study start and end dates
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Study design Whether participants were enrolled prospectively or retrospectively
Sampling strategy (consecutive or random)
Inclusion and exclusion criteria
Target condition Any form of plague or a particular form of plague (bubonic, septicaemic, pneumonic), with case de-
finitions
Participants Sample size
Characteristics: age, gender, comorbidities
Signs and symptoms presented
Recent prior antibiotic treatment
Index test Brand name, target antigen, batch numbers
Which biological sample was tested (urine, sputum, bubo aspirate)?
Transport and storage condition
Need for sample preparation
Who performed the test (including any special training provided)?
Where was the test performed (field or laboratory)?
Threshold considered for positive result?
Reference standard Which reference standard was used (culture, PCR, serology, combination)?
Which biological sample was tested (blood, urine, sputum, bubo aspirate)?
Who performed the reference standard test(s) (including training level)?
Where was the test performed?
How many observers or repeats were used?
Time between RDT and reference test?
Blinding of operator to RDT result?
Has the laboratory received quality accreditation by an external agency?
Index and reference stan-
dard test results
Numbers of true positives, false positives, true negatives, and false negatives
Number of uninterpretable or doubtful results
Notes Source of funding
Anything else of relevance
  (Continued)
 
PCR: polymerase chain reaction, RDT: rapid diagnostic test.
Appendix 3. Tailored QUADAS-2 tool
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Item Yes No Unclear
Domain 1: patient selection
Was a consecutive
or random sam-
ple of patients en-
rolled?
If the study reported consecutive enrolment or
random sampling of participants presenting
with suspicion of plague.
If participants were purpose-
fully selected, for example
based on previous test re-
sults.
If insufficient information
to make a decision on how
participants were select-
ed.
Was a case-control
design avoided?
This item will always be 'Yes' because we exclud-
ed case-control studies from this review.
Not applicable. Not applicable.
Did the study
avoid inappropri-
ate exclusions?
If no participants were excluded after inclusion
in the study, or if exclusions were clearly de-
scribed and appropriate (e.g. exclusion of the
participants with a known diagnosis).
If specific populations who
would be representative of
field conditions were exclud-
ed.
If unreported or insuffi-
cient information to make
a decision.
Did the study con-
sidered prior ad-
ministration of an-
tibiotics?
If participants who received antibiotics prior to
sample collection were excluded.
If participants who received
antibiotics prior to sample
collection were included.
If unreported or insuffi-
cient information to make
a decision.
Could the selection of participants have introduced bias?Risk of bias
(high, low, or un-
clear) 'High' if ≥ 1 of the above signalling questions
was 'No,' indicating that there was a concern.
'Low' if the answer to all 3
signalling questions was
'Yes.'
'Unclear' if the answer to
≥ 1 signalling question
was 'Unclear' and 0 are an-
swered 'No.'
Are there concerns that the included participants did not match the review question?Applicability con-
cerns
(high, low, or un-
clear)
'High' if the included participants were inherent-
ly different from the participants who would be
expected to receive the RDT.
'Low' if the included partic-
ipants were suspected to
have plague and matched
those who would be expect-
ed to receive the test.
'Unclear' if insufficient in-
formation on participant
characteristics to make a
decision.
Domain 2: index test
Were the index
test results inter-
preted without
knowledge of the
results of the ref-
erence standard?
If RDT was performed fully blinded to the refer-
ence standard result.
If reference standard result
was known prior to interpre-
tation of RDT result.
If blinding to reference
standard result was not
explicitly stated.
If a threshold was
used, was it pre-
specified?
If a threshold was prespecified. If a threshold was not pre-
specified.
If unreported.
Could the conduct or interpretation of the index test have introduced bias?Risk of bias
(high, low, or un-
clear) 'High' if the answer to either of the above sig-
nalling questions was 'No,' indicating that there
was a concern.
'Low' if the answer to both
signalling questions was
'Yes.'
'Unclear' if the answer to ≥
1 signalling question was
'Unclear' and 0 were an-
swered 'No.'
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Are there concerns that the index test, its conduct, or interpretation differed from the review question?Applicability con-
cerns
(high, low, or un-
clear)
'High' if the index test was not performed in field
conditions, or if the study described inappropri-
ate storage conditions for the index test.
'Low' if the study described
suitable storage conditions
for the index test and that the
index test was designed for
testing biological samples for
plague and was used in field
conditions.
'Unclear' if insufficient in-
formation to make a deci-
sion.
Domain 3: reference standard
Was the reference
standard likely to
correctly classify
the target condi-
tion?
This item will always be 'Yes' because a correct
reference standard was part of the inclusion cri-
teria of this review.
Not applicable. Not applicable.
Were the refer-
ence standard re-
sults interpreted
without knowl-
edge of the results
of the index tests?
This item will always be 'Yes' because all the ref-
erence standards (culture, PCR, and serology)
are objective tests with no room for subjective
interpretation of test results.
Not applicable. Not applicable.
Could the reference standard, its conduct, or its interpretation have introduced bias?Risk of bias
(high, low, or un-
clear) 'High' if the answer to either of the above sig-
nalling questions was 'No,' indicating that there
was a concern.
'Low' if the answer to both
signalling questions was
'Yes.'
'Unclear' if the answer to ≥
1 signalling question was
'Unclear' and 0 were an-
swered 'No.'
Are there concerns that the target condition as defined by the reference standard did not match the review
question?
Applicability con-
cerns
(high, low, or un-
clear) We answered this question as 'Low' concerns for all studies because diagnosis of plague by culture, PCR, or
paired serology does match the review question.
Domain 4: flow and timing
Was there an ap-
propriate inter-
val between index
test and reference
standard?
If no antibiotic was administered between sam-
ple collection for index test and reference stan-
dard, and if transportation of samples was < 7
days. We considered that the introduction of an-
tibiotics was more relevant than time between
collection of samples for both tests, as people
with suspicion of plague will be started on an-
tibiotics as early as possible, and might affect re-
sults (of culture mainly).
If antibiotic therapy was
started between sample col-
lection for RDT and reference
standard for a significant pro-
portion of participants, or if
transportation of samples
was > 7 days on average.
If there was insufficient in-
formation to make a deci-
sion.
Did all partici-
pants receive a
reference stan-
dard?
If all participants received a reference standard. If participants did not receive
a reference standard.
If there was insufficient in-
formation to determine
whether or not all partici-
pants received a reference
standard.
Did all partici-
pants receive the
If all the participants received the same refer-
ence standard.
If participants did not receive
the same reference standard.
If there was insufficient in-
formation to determine
whether or not all partic-
  (Continued)
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same reference
standard?
ipants received the same
reference standard.
Were all partici-
pants included in
the analysis?
If there were no withdrawals or exclusions (num-
ber of participants in the 2×2 table matched the
number of participants recruited into the study)
or if sufficient explanation was given for any dis-
crepancy.
If withdrawals or exclusions
were not explained or ac-
counted for.
In unreported or insuffi-
cient information to make
a decision.
Could the patient flow have introduced bias?Risk of bias
(high, low, or un-
clear) 'High' if ≥ 1 of the above signalling questions
was 'No,' indicating that there was a concern.
'Low' if the answer to all
above signalling questions
was 'Yes.'
'Unclear' if the answer to ≥
1 signalling question was
'Unclear' and none were
answered 'No.'
Applicability con-
cerns
Not applicable.
  (Continued)
 
PCR: polymerase chain reaction, RDT: rapid diagnostic test.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We conducted the review according to the published protocol (Jullien 2019).
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